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 INTRODUCTION 
Leukemias are neoplastic proliferation of  hematopoietic cells, which form a 
major proportion  of hematopoietic neoplasms, which are diagnosed worldwide. 
Leukemias are classified into two broad groups, myeloid and lymphoid, based 
on the origin of the leukemic stem cell clone. They cause progressive infiltration 
of the bone marrow and in certain forms the lymphatic tissues are particularly 
affected. Leukemia is the ninth most commonest cancer in the world, and is the 
ninth most common in males, which is 3% of total cancers in them , and is 
eleventh most common in females, 2% of total cancers in them. Age standardised 
rates for Asian males range from 6.3 to 10.6 per 100,000. In India the number of 
new cases were 13 per 100,000 men and women per year. Generally males are 
affected more than females. Two widely used classifications are used, one 
by the French, American, and British group called the FAB Classification, and 
other by the World Health Organisation (WHO Classification), based on the 
morphologic findings, genetic abnormalities, clinical and Immunophenotyping 
characteristics. Overall annual incidence in the general population is 4 per 
100,000 , with approximately 70% being Acute myeloid leukemia(AML). AML 
accounts for about 90% of the acute leukemias in adult population and 15% of the 
cases in childhood leukemias. Acute lymphoblastic leukemia(ALL) is primarily a 
childhood disease and commonly seen at a peak age of  2 or 3 years. Chronic 
myeloid leukemia (CML) occurs typically between ages 40 and 60, and the 
Chronic lymphoid leukemia (CLL) occur most after 65 years of age. This study 
attempts to evaluate the role of cytochemistry in classifying the various types of 
Leukemia and its subtypes, by a combination of morphology on the peripheral 
 blood smear, as well as correlate with the clinical and haematological findings of 
the cases, with available means in our laboratory. Cytomorphological assessment, 
based on FAB Classification was made, Immunophenotyping, was done for a 
select few cases, where there was doubt, or ambiguity, and its concordance with 
the cytochemical staining patterns and findings were taken into account. 
Peripheral blood smear, suspected of leukemia,in cases received at the 
Department of pathology, Thanjavur Medical college, was taken during the 
period from January 2015 to June 2016, and studied for this purpose. The study 
also aims to tell that the simple and cost effective method of cytochemical stains, 
a re  a  va luable  too l ,  in  a id ing  the  d iagnos t ic  methods  in  leukemia . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 AIMS AND OBJECTIVES 
 
1. To study the demographic data (Age and Sex) distribution in the various types 
of leukemias. 
 
2. To study the clinical and haematological manifestations of the various types of 
leukemias. 
 
3. To classify leukemias and subtype acute leukemias with the help of 
cytochemistry according to the cytomorphology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
MATERIAL AND METHODS 
 
The present study had a sample size of 56 cases of leukemia, diagnosed in the  
department of pathology, Thanjavur medical college. Those cases referred to the  
department of pathology, with clinical suspicion , were subjected to  peripheral  
smear study by  standard Romanowsky stains first, mainly by Leishman’s stain  
and a presumptive diagnosis was made. Following which peripheral blood smears  
were subjected to special cytochemical stains using Sudan Black B(SBB) and  
Periodic acid Schiff’s reagent stain(PAS).The percentage of blast cells were  
enumerated, and the cytomorphology studied based on their positive staining  
effects on the respective blood smears, were noted. Thereby the types and  
subtypes of leukemias were classified and reported as per FAB Classification.  
Relevant clinical history was obtained from each case, with paramaters relating to  
Splenomegaly,  Hepatomegaly,  and lymphadenopathy.  Hemato logical  
investigations were done on a three part automated cell counter, and values  
pertaining to Haemoglobin, Total count, and Platelet count were also noted.  
Clinical and Hematological correlation was thus made with the diagnosed cases,  
and statistical analysis was undertaken. In six cases, immunophenotyping using  
flow cytometry, and standard panel markers, was undertaken, where in, doubt and  
ambiguous nature was thought of, and its concordance patterns were also noted. 
 
 
 
 Inclusion criteria : 
Peripheral blood smear from all cases of all age groups who presented with  clinical  
features and abnormal haematological values suggestive of  leukemia. 
 
Exclusion criteria : 
Other Hematological neoplasms, like Lymphomas and multiple myelomas were  
excluded in the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 REVIEW OF LITERATURE 
Leukemias arise from abnormal proliferation of hematopoietic cells, mainly from  
the hematopoietic stem cells, the process of differentiation is abnormal and  
results in immature morphological appearance. They are a heterogenous group of  
malignancies with different clinical, morphological , immunological and  
molecular characteristics. Leukemia stands eleventh in the worldwide list of  
cancers, as per the world cancer research foundation data, with an incidence of  
352 per 1000, with 201 per 1000 in men, and 151 per 1000 in women as per the  
statistical data received by GLOBOCAN 2012, IARC Cancer base 2014, clearly  
showing a slightly more male preponderance. The SEER fact sheet shows number  
of new cases of  leukemia at 13.5 per 100,000 men and women per year, the  
Lifetime Risk of developing it standing at approximately 1.5 percent of men and  
women and the Relative surviving percent at 5 years being 59.7.In children it  
accounts for almost 30% of all cancers. 
 
AETIOLOGY :- 
  
Leukemia is a neoplastic disorder arising from the hematopoietic cell which has  
undergone intrinsic change, thereby escaping from the normal restraints imposed  
on its proliferative activity.  Population can consist of one or more different  
pathways of differentiation. The critical step in its leukemogenesis is the  
alteration of its DNA in the nucleus of its cell, in which it is initiated. 
 
  
Chromosomal abnormalities are common in leukemias and occur in all major  
categories of acute and chronic leukemias.Translocation, addition and deletion do  
occur in these abnormalities, thereby leading to produce a clone of cells which  
overtly becomes a leukemic cell clone undergoing blast changes. Translocation is  
seen, as evidenced in the Philadelphia chromosome, which is caused by the  
activation of the Abelson cellular proto-oncogene(c-abl) and its transfer to the  
breakpoint cluster region(BCR). 
 
Evidence that ionizing radiation is leukemogenic and the incidence of leukemia  
increasing in the cumulative dose received has been noted. Ionising radiation  
produces chromosomal abnormalities, thereby the process of  leukemogenesis.  
Exposure to high linear energy transfer radiation from alpha emitting radio-isotopes  
such as thorium dioxide increases the risk of leukemia.  
 
Exposure to chemicals over a period of time have been implicated too. Chemicals  
like benzene and its products,pesticides and herbicides, alkylating agents as in  
chemotherapy,  such as chlorambuci l  ,  melphalan,  procarbazine ,  and  
nitrosoureas,are noteworthy agents in their causage of chromosomal breakage,  
thereby producing leukemogenesis. 
 
Viruses like the Human T cell lymphotropic virus type-1 are known to cause  
oncogenetic process thereby producing T-Lymphocytic leukemia.  
 
 Genetic factors have also been implicated, a number of disorders with inherited  
abnormalities of  DNA have been associated with the increased incidence of  
leukemia. Children with Down’s syndrome have been found to have an increased  
incidence of leukemia with the presence of  the additional chromosome 21 in the  
cells.  Inherited disorders like Fanconi’s anemia, Bloom syndrome and Ataxia  
telengeictasia have an increased incidence of chromosomal breakage and  
leukemogenesis, leading to leukemia. Other conditions like Diamond-Blackfan  
syndrome, Noonan syndrome, Shwachman syndrome, Dubowitz syndrome,  
Kostmann syndrome, Poland syndrome, Rothmund-Thomson syndrome, Seckel  
syndrome, Werner syndrome(progeria), Wolf-Hirschhorn syndrome, MonoMAC  
and Emberger syndromes(GATA2 Mutation) have been implicated. 
 
A significant association between smoking tobacco and AML has been  
implicated, with a relative risk of about 1.5 to 2.0. 
 
An endogenous factor that increases increases risk of leukemia is Obesity, studies  
show AML being associated with it. 
 
Myelodysplastic syndromes(MDS), cause clonal progression, resulting in  
genomic instability and acquisition of additional mutations, thereby causing  
transformation into leukemic states. 
 
Other disorders like HIV Infection, Langerhans cell histiocytosis, thyroid  
disorders and polyendocrine disorders are known to cause leukemic states. 
 HEMATOPOIETIC LINEAGE:- 
Hematopoietic lineage consists of precursor and maturing myeloid cells,  
erythroid cells, monocytes, megakaryocytes and lymphoid cells. Mast cells and  
macrophages are both derived directly from the hematopoietic precursors and  
function as both hematopoietic cells and stromal cells of  the bone marrow. 
 
MYELOID SERIES :- 
This mainly consists of the granulocytic lineage, which includes neutrophils,  
eosinophils, basophils and their precursors. It is regulated by the granulocyte  
colony stimulating factor. 
The earliest of the neutrophilic granulocyte is the myeloblast which subsequently  
differentiates into promyelocyte, myelocyte , metamyelocyte, band cell, and  
segmented neutrophil. This maturation occurs in a progressive decrease in the  
nuclear-to-cytoplasmic ratio, loss of nucleoli, condensation of chromatin  
material, nuclear segmentation and simultaneous accumulation of primary and  
secondary granules. 
 
MYELOBLAST:- 
It measures 10-20µm in diameter. They are characterised by high nucleo- cytoplasmic  
ra t io with a large round ,  centra l ly placed nucleus ,  f inely dispersed  
chromatin, two to five prominent nucleoli, with scant to pale blue cytoplasm.  
This blast is subdivided into three subtypes, based on the presence of granules.  
Type 1 has no granules, Type 2 has less than 20 azurophillic granules and Type 3  
has more than 20 azurophillic granules 
 PROMYELOCYTE :- 
They are the largest granulocytic cells and measure 10-20µm in diameter. They  
have a large eccentrically placed round to oval nucleus with a prominent  
nucleolus and with moderate amount of basophilic cytoplasm containing a few to  
many purple-red primary azurophilic granules and a pale area called the Golgi  
zone. Promyelocytes and type 3 myeloblast are almost always indistinguishable  
and difficult to differentiate between them. 
 
MYELOCYTE :- 
This is the last stage capable of division in the lineage, and measures 10-18µm in  
diameter. These cells have a relatively small eccentrically placed round to oval or  
slightly indented nucleus with coarse, condensed chromatin and a moderate  
amount of cytoplasm containing puple-red primary azurophillic granules and  
light pink secondary granules. 
 
METAMYELOCYTES :- 
They measure 10-18µm in size, in this next stage of maturation . They have  
indented nuclei and abundant acidophilic cytoplasm, with predominant secondary  
granules. 
 
BAND CELLS :- 
They measure 10-16µ m in diameter and have a horse-shoe or band shape  
Nucleus (bilobed nucleus with no filaments) and abundant cytoplasm with  
secondary granules. 
  
SEGMENTED NEUTROPHILS :- 
They are the last in the series, measure upto10-16µ m in diameter and are  
characterised as many as five nuclear segmentations connected by each other  
with filaments. 
 
GRANULOCYTE SERIES IN A SMEAR :- 
 
 
 
 
 
 
 
 EOSINOPHILS :- 
Eosinophils demonstrate similar stages of proliferation and differentiation as  
neutrophils. The earliest morphologically identifiable cell is the eosinophil  
promyelocytes.They have round nuclei with dispersed chromatin and contain two  
types of granules, one the large, red-orange eosinophilic granules and the other  
the bluish granules. Eosinophilic myelocytes and metamyelocytes contain only  
the large red-orange eosinophilic granules.Mature eosinophils are similar or  
slightly larger in size than the neutrophils , containing bilobed nuclei, and  
numerous large eosinophilic cytoplasmic granules. 
 
BASOPHILS:- 
Basophils, like eosinophils also have similar stages of differentiation and  
proliferation as well as maturation. The earliest ones present are the basophil  
promyelocytes. Basophil promyelocytes, myelocytes and metamyelocytes have  
large, round, deeply basophilic granules. Mature basophils  are usually bilobed  
and have numerous coarse, deeply basophilic granules, that often overlie the  
nucleus. These granules stain metachromatically with Toluidine blue stain. 
 
MAST CELLS:-  
They are derived from multilineage myeloid stem cells and are closely related to  
basophils. They are of size 12-25µm in diameter. They are round, oval, or spindle  
shape cells, have a round to oval nuclei,with abundant cytoplasm containing  
numerous dark purple to red purple granules,they are easily recognised in smears  
and aspirates stained by Wright-Giemsa stain. 
  
MONOCYTES AND MACROPHAGES :- 
They are derived from the same progenitor cells as the granulocytic series. The  
p r o l i f e r a t i o n  a n d  d i f f e r e n t i a t i o n  o f  t h e s e  c e l l s  a r e  c o n t r o l l e d  b y  
monocyte/macrophage colony stimulating factor. Gradual nuclear folding and  
acquisition of cytoplasmic granules characterize the monocytic differentiation  
and maturation. These stages include monoblast, promonocyte, mature monocyte  
and macrophage. Monoblasts are similar to myeloblast except that they have  
slightly lobulated or indented nuclei with scant agranular cytoplasm, and has 1 to 4 
nucleoli.Promonocytes are seen earliest, measure 15-20µm in diameter and have large,  
round, lobulated or folded nucleus with fine chromatin and a moderate amount of  
cytoplasm containing few azurophillic granules. Mature monocytes have  
eccentrically placed , oval, lobulated, folded or indented nuclei with fine lacy  
chromatin, and abundant blue grey, vacuolated cytoplasm, and they measure 15- 
18µm in diameter. Monocytes are released from bone marrow into the blood  
circulation , migrating to different body sites, where they transform into tissue  
macrophages or histiocytes. Macrophages are larger than monocytes and function  
as phagocytic cells in the bone marrow and measure 20-70µm in diameter, have  
varying size and shape, cytoplasm is abundant having vacuoles, and may contain  
cell debris and hemosiderin. The nucleus can also be varying in size with round  
to oval or indented shape. 
 
 
 
 LYMPHOID SERIES:- 
Lymphoid cells are also derived from multipotential stem cells and are primarily  
regulated by interleukins. 
 
Lymphoblast is the earliest morphologically recognisable cells, 12-20µm in  
diameter,they are characterized by high nucleo-cytoplasmic ratio, round to oval  
nuclei with fine coarser chromatin, having one or two nucleoli, and having a  
small amount of basophilic agranular cytoplasm. They are sometimes difficult to  
differentiate from other blast cells. The lymphoid maturation results in two group  
of cells, T and B lymphocytes. B cell maturation occurs in marrow where as T  
cell maturation is complete in thymus. Prolymphocyte is intermediate between 
lymphoblast and mature lymphocyte, usually 10-12µm, resembles a mature 
lymphocyte, with fine blastic chromatin, having a single large nucleolus and pale blue 
cytoplasm 
 
Large lymphocyte is 10-15µm in diameter, with a centrally or eccentrically   
placed nucleus, having a clear blue cytoplasm and no nucleoli. Nuclear chromatin  
is less condensed. 
Small lymphocytes are 7-10µm in diameter, slightly larger than a mature RBC,  
nuclear chromatin is densely coarse, with a thin rim of pale blue cytoplasm, have  
an inconspicuous nucleoli too, and these are the mature forms. Morphologically T  
and B lymphocytes are indistinguishable and can only be differentiated by  
surface antigen detection by immunophenotyping.  
 Plasma cells measure 10-18µm in diameter and are the last stage of maturation in  
the B cell lineage. They are present in low numbers in the marrow. They are  
characterized by eccentrically placed nucleus with coarse chromatin and amply  
deeply basophilic cytoplasm containing a perinuclear golgi zone. 
In adults, lymphocytes constitute less than 20% of the total nucleated cells of the  
marrow, however in children , younger ones less than 6years of age have as many  
as 40% of the nucleated cells in the marrow. 
 
 
Lymphoblast   prolymphocyte         lymphocyte 
 
With this knowledge of basic myeloid and lymphoid series, we now classify 
the  myeloid and lymphoid cell neoplasms, based on their morphologic characteristics  
and the clinical presentation as well as with their cytochemical and  cytogenetics.  
 
  
 CLASSIFICATION OF LEUKEMIAS 
Leukemias are now classified as per the FAB(French American British)  
classification, as well as the WHO(World Health Organisation) classification.1,8  
The FAB Classification is purely based on the cytomorphological pattern of the  
presentation seen in it. It relates subtypes to the stages of differentiation and  
myeloid development and is easy to understand. Has a cut off value for blasts,  
30%  or more of its presence as the diagnostic point. But the categories do not  
separate subtypes by prognostic relevance, and hence has largely supplanted by  
the WHO classification. Revised FAB classification included paramaters which  
included prognosis, incorporating cytogenetics and immunophenotyping 
The WHO classification, is based on morphology,history, clinical picture,  
cytogenetics and flow cytometric analysis with immuno markers. The cut off  
value of percentage of blasts being 20% or more in the revised FAB Classification 
also. The significance here lies for prognosis and therapy.  
 
In our study we include FAB classification, incorporating the simple to  
understand, cytochemical analysis, as well as the morphology, which is easy to  
classify and corroborate the findings in the context of feasible standards, and with  
available means in our backyard. We also do immunophenotyping in a select few  
doubtful cases which corroborated with our findings initially. 
 
 
 
 WHO CLASSIFICATION. 1 :- 
1.  Minimal deviation neoplasms (no increase in blast cells(<2%)are   evident in  
the marrow) 
A. Underproduction of mature cells is prominent 
   
  1. Clonal anemia (refractory sideroblastic or non-sideroblastic) 
 
  2. Clonal  bi or tricytopenia 
  
  3. Paroxysmal nocturnal hemoglobinuria 
 
B. Overproduction of mature cells is prominent 
    
   1. Polycythemia vera 
    
   2. Essential thrombocythemia 
 
2. Moderate deviation neoplasms(very small proportion of leukemic blast  cells 
    present in marrow) 
 A. Chronic myelogenous leukemia 
               1. Philadelphia(Ph) chromosome positive  BCR Rearrangement positive  
                 (~6%) 
               2. Philadelphia chromosome negative BCR Rearrangement negative   
                  (~4%) 
            B. Primary myelofibrosis ( chronic megakaryocytic leukemia) 
            C. Chronic eosinophilic leukemia 
                  1. PDGFR Rearrangement positive 
                  2. FGFR Rearrangement positive 
             D. Chronic neutrophilic leukemia  
                   1. CSF3R Rearrangement positive 
                  2. CSF3R and SETBP1 Rearrangement positive 
                  3. JAK2v617 Rearrangement positive 
         E. Chronic basophilic leukemia 
         F. Systemic mastocytosis (chronic mast cell leukemia) 
             1. KITD816V mutation positive (~90%) 
             2. KITV560G mutation positive (rare) 
3. Moderately severe deviation of neoplasms( moderate concentration of   
     leukemic blast cells present in marrow) 
A. Oligo myelogenous leukemia(refractory anemia with excess blasts) 
B.Chronic myelomonocytic leukemia 
        C.Atypical myeloproliferative disease (atypical chronic myelogenous      
            leukemia) 
        D.Juvenile myelomonocytic leukemia 
4.Severe deviation neoplasms ( leukemic blasts or early progenitor cells frequent   
     in the marrow) 
A. Phenotypic variants of acute myelogenous leukemia 
1.Myeloblastic (granuloblastic) 
           2.Myelomonocytic ( granulomonoblasts) 
           3.Promyelocyte 
           4.Erythroid 
           5.Monocytic 
           6.Megakaryocytic 
           7.Eosinophilic 
            8.Basophilic 
           9.Mastocytic 
           10.Histiocytic or dendritic      
B. High frequency genotypic variants of acute myelogenous leukemia  
 
[t(8;21) , Inv16 or t(16;16), t(15;17) or (11q23)] 
C.Myeloid sarcoma 
      D.Acute biphenotypic (myeloid lymphoid markers) leukemia 
      E.Acute leukemia with lymphoid markers evolving from a prior clonal  
          disease 
                                    
2008 WHO CLASSIFICATION OF ACUTE MYELOID LEUKEMIA. 2,4,5 
Acute myeloid leukemia and related neoplasms 
1.Acute myeloid leukemia (AML) with recurrent genetic abnormalities 
   AML with t(8;21)(q22;22) (RUNX1-RUNX1T1) 
   AML with inv(16)(p13,1q;22) or t(16;16)(p13,1;q22) (CBFB-MYH11) 
   Acute promyelocytic leukemia with t(15;17)(q22;q12) (PML-RARA) 
   AML with t(9;11)(p22;q23) (MLLT3-MLL) 
   AML with t(6;9)(p23;q34) (DEK-NUP214) 
   AML with inv(3)(q21;q26.2) or t(3;3)(q21;q26.2) (RPN1-EV11) 
   AML (Megaryoblastic) with t(1;22)(p13;q13) (RBM15-MKL1) 
   Provisional entity : AML with mutated NPM1 
   Provisional entity: AML with mutated CEBPA 
2. AML with myelodysplasia related changes 
3. Therapy related myeloid neoplasms 
 4. AML Not otherwise specified 
     AML with minimal differentiation 
     AML without maturation 
     AML with maturation 
     Acute myelomonocytic leukemia 
     Acute monoblastic/monocytic leukemia 
     Acute erythroid leukemia 
        Pure erythroid leukemia 
        Erythroleukemia, erythroid/myeloid 
     Acute megakaryoblastic leukemia 
     Acute basophilic leukemia 
     Acute panmyelosis with myelofibrosis 
5.Myeloid proliferations related to Down syndrome 
     Transient abnormal myelopoiesis 
     AML associated with Down syndrome 
6.Myeloid sarcoma 
7. Blastic plasmacytoid dendritic cell neoplasm 
 
 
Myeloproliferative Neoplasms (MPNs) 
1.Chronic myelogenous leukemia, BCR-ABL1 Positive 
2.Chronic neutrophilic leukemia 
3.Polycythemia vera 
4.Primary myelofibrosis 
 5.Essential thrombocythemia 
6.Chronic eosinophilic leukemia, not otherwise specified 
7.Mastocytosis 
8.MPN, Unclassifiable 
Myeloid and Lymphoid neoplasms associated with eosinophilia and  
abnormalities of PDGFRA,PDGFRB or FGFR1 
1.Myeloid and lymphoid neoplasms associated with PDGFRA rearrangement 
2.Myeloid neoplasms associated with PDGFRB rearrangement 
3.Myeloid and lymphoid neoplasms associated with FGFR1 abnormalities 
 
Myelodysplastic/Myeloproliferative neoplasms (MDS/MPNs) 
1.Chronic myelomonocytic leukemia 
2.Atypical chronic myeloid leukemia, BCR-ABL1 Negative 
3.Juvenile myelomonocytic leukemia 
4.Myelodysplastic/Myeloprolifertive neoplasm, unclassifiable 
5.Provisional entity: Refractory anemia with ring sideroblasts and thrombocytosis 
 
 
Myelodysplastic syndrome (MDS) 
1.Refractive cytopenia with unilineage dysplasia 
    Refractive anemia 
    Refractive neutropenia 
    Refractive thrombocytopenia 
2.Refractive anemia with ring sideroblasts  
 3.Refractive cytopenia with multilineage dysplasia 
4.Refractive anemia with excess blasts 
5.MDS with isolated del(5q) 
6. MDS, unclassifiable 
 
 2008 WHO CLASSIFICATION OF THE LYMPHOID NEOPLASMS .2,4,5 
1.Precursor lymphoid neoplasms 
    B lymphoblastic leukemia/lymphoma 
    T lymphoblastic leukemia/lymphoma 
2.Mature B cell neoplasms 
    Chronic lymphocytic leukemia/small lymphocytic lymphoma 
    B cell prolymphocytic leukemia    
    Splenic B cell marginal zone lymphoma 
    Hairy cell leukemia 
    Lymphoplasmacytic lymphoma  
    Heavy chain disease 
    Plasma cell neoplasm 
    Follicular lymphoma 
    Mantle cell lymphoma 
    Diffuse large B cell lymphoma 
    Burkitt lymphoma 
3.Mature T and NK cell neoplasms 
    T cell prolymhocytic leukemia 
    T cell large granular lymphocytic leukemia 
      Mycosis fungoides 
     Sezary syndrome 
     Peripheral T cell lymphoma, not otherwise specified 
     Angioimmunoblastic T cell lymphoma 
     Anaplastic large cell lymphoma 
     Adult T cell leukemia/lymphoma 
     Extranodal NK/T cell lymphoma, nasal type 
4.Hodgkin lymphoma 
     Classical Hodgkin lymphoma 
       Nodular sclerosis 
       Mixed cellularity 
       Lymphocytic rich 
       Lymphocytic depleted 
    Nodular  lymphocytic predominance Hodgkin lymphoma 
 
 
WHO CLASSIFICATION OF ACUTE MYELOID LEUKEMIA AND  
RELATED PRECURSOR NEOPLASMS IN CONTEXT TO FAB  
CLASSIFICATION.3 
Acute myeloid leukemia and related neoplasms 
1.Acute myeloid leukemia (AML) with recurrent genetic abnormalities 
   AML with t(8;21)(q22;22) (RUNX1-RUNX1T1)  - FAB –M2 
   AML with inv(16)(p13,1q;22) or t(16;16)(p13,1;q22) (CBFB-MYH11) –M4eo 
   Acute promyelocytic leukemia with t(15;17)(q22;q12) (PML-RARA)–M3,M3v 
    AML with t(9;11)(p22;q23) (MLLT3-MLL) – FAB -M4 , M5 
   AML with t(6;9)(p23;q34) (DEK-NUP214) 
   AML with inv(3)(q21;q26.2) or t(3;3)(q21;q26.2) (RPN1-EV11) 
   AML (Megaryoblastic) with t(1;22)(p13;q13) (RBM15-MKL1) 
   Provisional entity : AML with mutated NPM1 
   Provisional entity: AML with mutated CEBPA – FAB Variable 
2. AML with myelodysplasia related changes – FAB Variable 
3. Therapy related myeloid neoplasms – FAB Variable 
4. AML Not otherwise specified 
     AML with minimal differentiation – FAB – M0 
     AML without maturation  - FAB – M1 
     AML with maturation -  FAB – M2 
     Acute myelomonocytic leukemia – FAB – M4 
     Acute monoblastic/monocytic leukemia – FAB – M5a , M5b 
     Acute erythroid leukemia – FAB – M6a ,M6b 
        Pure erythroid leukemia 
        Erythroleukemia, erythroid/myeloid 
     Acute megakaryoblastic leukemia – FAB – M7 
     Acute basophilic leukemia 
     Acute panmyelosis with myelofibrosis 
5.Myeloid proliferations related to Down syndrome 
     Transient abnormal myelopoiesis 
     AML associated with Down syndrome 
6.Myeloid sarcoma 
 7. Blastic plasmacytoid dendritic cell neoplasm 
8. Acute leukemias of ambiguous lineage, undifferentiated and mixed types 
Revised update of the WHO CLASSIFICATION 2016.23 
There has been a revision of the WHO classification of tumours of hematopoietic  
and lymphoid tissues, at the time of this study. It incorporates clinical features,  
morphology, immunophenotyping, cytogenetics and molecular genetics, to define  
the various entities for clinical importance. Reasons for its revision has been,  
discovery of new molecular features with regards to diagnostic and prognostic  
markers ,  in  unders tanding bet ter  the  pathology.  Secondly,  improved  
standardisation and characterisation of morphological features,aiding in the  
d i f f e r e n t i a t i o n  o f  t h e  d i s o r d e r s ,  s u c h  a s  t h e  B C R - A B L  n e g a t i v e  
myeloproliferative neoplasms,which has increased the reliability of the diagnosis.  
Thirdly an integrated approach was postulated on the basis of hematologic,  
morphologic, cytogenetic, and molecular genetics, which was validated.  
The changes include, removal of Mastocytosis from the MPN list, due to its  
unique clinical and pathological features and is considered a separate disease  
category in the classification. Bone marrow karyotyping in the criteria for chronic  
phase of CML, monitoring of the fusion gene in accelerated phase during therapy,  
looking for extramedullary accumulation for blasts in blast phase, are changes  
made now. CALR mutations in MPN, CSF3R mutations in Chronic Neutrophilic  
Leukemia have been recognised, Bone marrow criteria in polycythemia vera has  
been incorporated, marrow fibrosis to differentiate pre-fibrotic from primary  
myelofibrosis and Essential thrombocythemia, and to have a say on its prognosis,  
and have an accurate histologic diagnosis. 
 FAB CLASSIFICATION.3,4,19 
It was devised by a group of French, American , and British haematologists in  
1976, based on blood and bone marrow morphological features defined by  
Romanowsky’s stains and cytochemical staining patterns. The FAB classification  
remains the gold standard against which the WHO classification was developed.  
It primarily divides leukemias into acute and chronic types. The myeloid ones  
were Acute myeloid leukemia(AML) and chronic myeloid leukemia(CML). The  
lymphoid ones were Acute lymphoblastic leukemia(ALL) and chronic  
lymphocytic leukemia(CLL). The assigned cut of percentage of blasts in  
peripheral blood and bone marrow smears being  >30% in them. It was relatively  
s imp le  to  unde r s t and  a s  we l l  a s  eas y to  c l a s s i f y acc o rd ing  to  the  
cytomorphological pattern observed. 
 
 
FAB CLASSIFICATION OF ACUTE MYELOID LEUKEMIA.3,4,19 
AML- M0 Minimally differentiated 
AML- M1 Without maturation 
AML-M2 With maturation 
AML-M3 Promyelocytic 
AML-M4 Myelomonocytic 
AML-M5  
          M5a- monoblastic (>80% monoblasts) 
          M5b- monocytic (<80% monoblasts) 
          M5c- malignant histiocytic spill over 
 AML- M6 – Erythroid 
           M6a- Erythroleukemia 
           M6b- pure erythroid leukemia 
AML-M7 – Megakaryocytic leukemia 
FAB CLASSIFICATION OF CHRONIC MYELOID LEUKEMIA.3,4,19 
Chronic granulocytic leukemia (CGL) Classical CML 
 Atypical chronic myeloid leukemia (a CML) 
 Chronic myelomonocytic leukemia (CMML) 
FAB CLASSIFICATION OF ACUTE LYMPHOBLASTIC  
LEUKEMIA.3,4,19 
Acute lymphoblastic leukemia 
L1- Subtype 
L2- Subtype 
L3- Subtype 
FAB CLASSIFICATION OF CHRONIC LYMPHOCYTIC  LEUKEMIA.3.4 
   CLL- Prolymphocytes >10% 
   CLL-PLL – Prolymphocytes 11-55% 
   PLL- Prolymphocytes more than 55% 
 
CYTOMORPHOLOGY IN FAB CLASSIFICATION.3,4 
ACUTE MYELOID LEUKEMIA 
AML M0  with minimal differentiation 
The blasts are usually 15-18µm in diameter, the nucleus occupies most of the  
cell, the nuclear membrane is fine, the nuclear chromatin is open and fine, with 1- 
 3 nucleoli. The cytoplasm is pale blue, forming a rim around the nucleus, and  
does not have any inclusions. Less than 3% of  blasts show both myeloperoxidase  
and Sudan black B(SBB) Positivity. These cells are CD 13, CD33, and CD 117  
positive by flow cytometric analysis for immunophenotyping, which show  
confirmation of AML lineage. CD15, CD36, and CD64  are negative for  
maturity. Erythroid precurs show dyserythropoiesis and megaloblastic features. 
 
AML M1 without maturation 
The blasts are 15-18µm in diameter, the nucleus occupies most of the cell, the  
nuclear membrane is fine, nuclear chromatin is fine, 2 to 3 nucleoli are also seen.  
The cytoplasm is pale blue in nature, forming a rim around the nucleus, and may  
contain thin pink rod like structures called Auer rods. This is formed by the  
condensation of the primary granules and when present are diagnostic of AML.  
M1is differentiated from M2, by the presence of more than 90% blasts and less  
than 10% containing other maturing granulocytic component. M1 occurs in  
almost 15-20% of cases of AML. Larger nucleocytoplasmic ratio is also seen.  
More than 3% of blasts are myeloperoxidase and Sudan black B(SBB) positive.  
Acid phosphatase shows diffuse positivity. 
 
AML M2 with maturation 
The blasts are 15-18µm size in diameter, the nucleus occupies most of the cell,  
nuclear membrane is fine, nuclear chromatin is fine, 2 to 3 nucleoli are seen. The  
cytoplasm is pale blue, forms a rim around the nucleus, contains early granulation  
and thin rod like pink structures called Auer rods. More than 30 to 100% of blast  
 cells are seen, which are positive for myeloperoxidase and Sudan blackB(SBB)  
stains. Alpha naphthyl chloracetate esterase reaction is also positive in them.More  
than 10% of myeloid precursors are also present. This is the commonest subtype  
of AML seen in over 30% of cases. The cytogenetic abnormality noted is t(8;21).  
Often young individuals are affected. 
 
AML M3 Promyelocytic 
The blast is promyelocytic, 18-20µm in diameter size, the nucleus has reticular  
chromatin, has 1 to 2 nucleoli. The nucleus appears to be folded on itself or may  
be bilobed. The cytoplasm is moderate in amount and has pink azurophilic  
granules. Many Auer rods can be seen, and these cells are called Faggot cells.  
Sometimes these cells have less granulation, so they are called hypogranular  
variant. The hypergranular variant is seen in 5to10% of AML cases. Dense  
granules obscuring the nucleus are seen, Auer rods can be seen in bundles and are  
larger in size, a few of them show Phi body too, paranuclear hof is also present.  
Myeloperoxidase is strongly positive, as well as Sudan black B. PAS can show  
cytoplasmic positivity.More than 30% blasts are seen. 90% of the blasts are  
specific esterase positive.Majority of the hyper granular variant are associated  
with leucopenia .Hypogranular variant, have sparse finer microgranules, have a  
bilobed or reniform or convoluted nucleus, and apparently agranular cytoplasm.  
Few cells have Auer rods, or Phi body. Most often the leucocyte count are higher  
in hypogranular variety. Cells usually are indistinct from both types, and should  
be carefully evaluated morphologically as well as by cytochemistry and  
cytogenetic evaluation, so as to distinguish it from AML M5b type, as  
 monoblasts like cells are encountered. PML- RARA alteration can be assayed by  
PCR as well as by FISH. The cytogenetic alteration seen is t(15;17). CD13 and  
CD33 are positive by flow cytometry,immature markers CD34 ,HLA-DR, CD15  
and CD65 are negative. 
 
AML M4 myelomonocytic 
This variant has two types, one like the promyelocytic, and the monocytic  
Component, the other. It occurs in almost of 20% of cases. The myeloblasts are  
upto 20% of monocytes and monoblasts, more than 30% coexist as blastic  
components. Increased monocytes are seen in peripheral blood. The blasts are 20- 
22µm in diameter, nucleus may be round or convoluted as in promyelocytes, has  
reticular chromatin, and 2 to 3 nucleoli. The cytoplasm is abundant, vacuolated,  
and may contain  few azurophil ic  granules and sometimes Auer  rods.  
Myeloperoxidase ,Sudan black B and Non specific esterase are positive,  
especially in the monocytic component. A distinct variant M4eo has eosinophilic  
differentiation and a cytogenetic abnormality of inversion 16. They have more  
than 5% eosinophilic precursors with basophilic granules too which is diagnostic.  
Immunophenotyping expresses CD64, CD14, CD11b, CD11c in the monocytic  
component, and are positive in CD34 and CD117  in the M4eo entity. Variable  
expression for CD13,CD33,MPO, and CD15 as well as HLA-DR are seen.  
Double esterase stains, chloracetatase esterase (CAE) for myeloid differentiation   
and non specific esterase for monocytic differentiation are useful to distinguish  
M4 from M2 and M5. 
 
 AML M5 Monocytic 
In this type, the blast is predominantly monocytoid, and restricted to the  
monocyte series, usually has high cell counts too, and a propensity to infiltrate  
skin, gums, meninges , lungs and lymph nodes with rapid progression. This  
accounts for 7 to 10% of AML cases, and is uncommon. Three types of it has  
been recognised,  M5a,M5b, and M5c. M5a type has predominant monoblasts ,  
almost  more than 80% are seen in them, promonocytes and monocytes are less  
than 20%. The monoblasts are large cells having pale blue basophilic cytoplasm  
having vacuolations , with few granulations, nuclei are round to oval, having a  
lacy fine chromatin , which contain more than 1 nucleoli. Blasts show non  
specific esterase positivity with sodium fluoride inhibition, weak granular  
myeloperoxidase positivity, and granular positivity with Sudan black staining in  
cytochemistry. M5b type has predominant promonocytes in the marrow and  
monoblasts are less than 80%. Promonocytes have abundant cytoplasm with  
azurophilic granules, the nuclei is lobulated or convoluted with prominent  
nucleoli.  Monocytes have lesser nucleocytoplasmic ratio, with lobulated or  
reniform nuclei and basophilic cytoplasm which is vacuolated and borders are  
irregular, the nuclear chromatin is condensed and have variable nucleoli. They  
are positive to non specific esterase(NSE) staining and are similar to monoblasts  
in immunophenotyping. Promonocyte enumeration helps in distinguishing M5b  
from chronic myelomonocytic leukemia. In addition to cytochemistry , serum and  
urine muramidase levels are raised. M5c is rare and show malignant histiocytic  
spill in the peripheral blood. Variable expression of immunomarkers are seen in  
AML M5. CD33, CD13, CD 14, CD 11, CD 11b , CD 11c, lysozyme, CD64 and  
 CD68 are positive. HLA-DR is also positive. Myeloperoxidase can be weakly  
expressed. 
 
 
AML M6 with erythroid differentiation 
This type also is a rarer form constituting 3 to 4% of AML cases. It is seen with  
severe anemia. Two types are present M6a and M6b. M6a has more than 50% of  
blasts in marrow and non erythroid cells being more than 20%. Erythroid  
component is prominently seen in this type, the erythroblast show megaloblastoid  
or macronormoblastic reaction , with nucleocytoplasmic asynchrony. Blasts can  
have binucleus , the nucleus is multilobed, few ring sideroblasts are seen.  
Cytoplasm has vacuoles. Some blasts can have Auer rods and can be dysplastic.  
Myeloperoxidase stains positive,the erythroid component can demonstrate coarse  
granules in the cytoplasm which show cytoplasmic granular positivity with Per  
iodic Schiff”s stain (PAS). Focal non specific esterase is also seen positive.CD71,  
CD 117 and glycophorin A also are positive with immunophenotyping. CD13  
and CD33, which are myeloid markers are dimly positive too in this type.M6b is  
pure erythroid type, the proerythroblastic population is more than 80% of the  
marrow cells. The blast cells are large with basophilic cytoplasm and has  
vacuoles, the nuclei are round with fine chromatin and 1 to 2 nucleoli. M6b  
expresses glycophorin A , haemoglobin A . MPO is absent CD 34, CD 41, CD61,  
CD64, and HLA-DR are negative in immunophenotyping. 
 
  
 AML M7 megakaryocytic leukemia 
In this variant the cell line involved is megakaryoblastic. The blasts superficially  
resembles lymphoblasts. It is seen very uncommonly, and is present in 8 to 10%  
of adult cases and 2 to 3% of cases in children. It can also occur in 20% of  
Philadelphia chromosome positive chronic myeloid leukemia patients too.  In this  
type more than 20% of the blasts are in the bone marrow nucleated cells,and  
more than 50% are of the megakaryocytic lineage, and flow cytometry shows  
positivity for CD41 and CD61 which are platelet markers. The megakaryoblasts  
are large cells and variable in size, having abundant pale blue cytoplasm, 
cytoplasmic protusions, with blebs, the nuclei are rounded with condensed  
chromatin, having a single or multiple nucleoli. Micromegakaryocytes and  
fragments can also be seen. These micromegakaryocytes are small cells with  
round nuclei having condensed chromatin and mature cytoplasm, these are not  
included in the blast count too. Bizarre sized platelets are also present. The blasts  
are negative for Myeloperoxidase and Sudan black B(SBB) cytochemical stains.  
Periodic acid schiff’s stain(PAS) show cytoplasmic granular positivity, some  
blast may show non specific esterase positive which is fluoride sensitive. Other  
markers like CD34,CD45 and HLA-DR are negative. Myeloid markers like CD13  
and CD33 may be positive. 
 
CHRONIC MYELOID LEUKEMIA 
C h r o n i c  g r a n u l o c y t i c  l e u k e m i a  ( C G L )  C l a s s i c a l  C M L 
This is the commonest form of CML, and is either philadelphia chromosome  
positive or negative, but BCR/ABL1 positive, primarily seen in the fifth and sixth  
 decades of life. Males are affected slightly more than females. Onset is gradual  
with non specific symptoms, 50% of them are asymptomatic and diagnosed at  
routine blood exam. There are three different phases of CML. Chronic phase ,  
accelerated phase and blast phase with crisis. 
Chronic phase  
In the chronic phase , the total count varies from 30 × 109/L to 1000×109/L,  
and can even be above it too. The leucocytosis has mainly neutrophils, and all  
stages of white cells from myeloblasts to mature neutrophils. Dysplasia of  
myeloid cells are usually not seen. Myelocytes and mature cells are mostly seen  
with blasts usually being less than 10%, often less than 3%. Myelocyte bulge is  
the major immature cell present, the neutrophilic precursors are usually normal,  
later stages can present with Pelger Huet cells and hypersegmented neutrophils.  
Hypogranular basophils are seen in this phase, mild eosinophilia is also observed  
with both basophilic and eosinophilic granules. Monocytes can also be  
present,and when seen is usually associated with BCR ABL 1 and needs to be  
d i f f e ren t ia ted  f rom chronic  mye lomonoc yt ic  leukemia  and  juveni le  
myelomonocytic leukemia. Most of these cases have normocytic normochromic  
anemia,with nucleated RBCs also seen with some nuclear budding. Presence of  
anisopoikulocytosis and tear drop cells are suggestive of marrow fibrosis.  
Platelets are moderately increased in this phase, can be upto 1000×109/L ,  
and vary in size and shape with lack of granules. Some megakaryocytes are also  
seen with fragments too. Platelet function can also be deranged. Neutrophil  
alkaline phosphatise score is markedly reduced and can be as much as 0 to 20 ,  
normal being 40 to 100. Marrow is usually hypercellular,containing hyperplastic  
 hematopoietic cells, and has marked myeloid hyperplasia, with M:E Ratio being  
as much as 15:1 to 32:1. Proliferation of neutrophilic precursors are seen, with  
slight increase in basophilic precursors and eosinophilic precursors, myeloblasts  
are usually less than 5%. Megakaryocytes are smaller in size and usually a  
dysmegakaryopoietic picture is present. Erythroid series is  decreased,  
morphologically normal, and unevenly distributed in focal areas. Macrophages  
with linear striations or with wrinkled granular cytoplasm having a sea blue  
colour, also called as Pseudo Gaucher cells or Sea blue Histiocytes are also seen,  
which is mainly due to increased lipid formation. The NAP score helps in  
differentiating CML from leukemoid reaction. Sudan black B(SBB) can be  
variably positive, showing coarse granules, as well as MPO too. Molecular  
findings in chronic phase are , to detect Philadelphia chromosome and the  
presence of BCR-ABL1 fusion gene. The chimeric size of the protein is  
210kd,which is the p210 fusion protein.  
Accelerated phase 
In the accelerated phase, usually more than 5 to 20%, in the range of 10 to 19%.  
There is persistent basophilia , which is more than 20% in the peripheral blood.  
The total count values can be more than 10 × 109/L, and will be increasing.  
Thrombocytopenia is a key feature, where the count gets reduced below            
100 × 109/L . Myeloblasts are seen upto 19% in the smears. Marrow shows  
similar blast range upto 19%, and  are seen in clusters, with promyelocytes seen  
more in the paratrabecular and perivascular areas.increasing anemic picture is  
also seen. Immunophenotyping with CD34 markers is positive and focal.  
Additional clonal cytogenetic and chromosomal abnormalities are also seen like  
 trisomy 8, isochromosome 17q, or duplication of the Philadelphia chromosome.  
Megakaryocytic series proliferation is associated with reticulin fibrosis and  
granulocytic dysplasia. Granulocytic dysplasia can be well seen by Sudan black B  
(SBB) staining as they stain granules black in the cytoplasm. Majority of the   
cases progress to blast crisis gradually. 
 
Blast crisis (Blastic phase)  
The chronic phase gets transformed to terminal phase of blast crisis in almost  
70% of the cases. Here the blasts are more than 20%. The clinical picture looks  
that of acute leukemia. Blastic phase is myeloid in 60 to70% of cases. MPO and  
SBB staining is weak and variable with subtype being either M1, M2, M4, M5,  
M6, or M7. M3 transformation is very rare. About 10 to 15% undergo M7  
t ransformat ion.  Basophi ls  are  seen,  and increase  to  more than 20%.  
Thrombocytopenia is also present with bleeding manifestations. Bone marrow  
fibrosis can also develop, leading to marrow failure. Flow cytometry  for  
immunophenotyping with CD13, CD33, CD41, CD14, CD117, CD34, HLA-DR,  
is positive for these myeloid blast cells. Aberrant lymphoid antigens can also be  
expressed. Nearly 15 to 30% of cases undergo lymphoblastic blast crisis, this can  
be identified with immunophenotyping with CD10, TdT and CD19 markers  
showing the aberrant nature of the myeloid neoplasm. Some of them have a  
mixed phenotype of acute leukemia. 
 
  
 Atypical Chronic myeloid leukemia (aCML)  
This variant of CML is Philadelphia chromosome negative , there is increase in  
monocytoid population of cells, and lie in an intermediate position between  
classical CML and chronic myelomonocytic leukemia (CMML). There is  
prominent dysplasia of granulocytes , megakaryocytic and and erythroid series  
t o o .  T h e  t o t a l  c o u n t  i s  l o w e r ,  u s u a l l y  b e t w e e n  2  t o  5  ×  1 0 9 / L .  
Myelocytes are less in number, but monocytoid and atypical neutrophilic cells are  
more . Thrombocytopenia and anemia is more frequent in them. BCR-ABL1  
fusion gene is negative in these cases. 
 
Chronic myelomonocytic leukemia ( CMML)  
This type of CML is Philadelphia chromosome negative , and now classified  
under the MDS/MPN category of the 2008 WHO Classification. There is absolute  
monocytosis  with more than 1×109 /L ,  which is  a prominent feature.  
Thrombocytopenia is very common unlike classical  CML. Normocytic  
normochromic  anemia i s  present .Total  leucocyt ic  count  var ies  f rom                      
0 .9  t o  160  ×10 9 / L   and  can  r i s e  modera t e l y .  B one  mar r ow  sho ws  
hypercellularity with granulocytic and monocytic hyperplasia, features of  
myelodysplasia of the hematopoietic cell lines are evident. Basophils are more  
than 2%, monocytes 3 to 10%, with severe granulocytic dysplasia, blasts more  
than 2% and immature granulocytes 10 to 20%. MPO and SBB stain variably.  
CD45, CD68 and lysozyme are positive for immunostaining. Cytogenetics show  
they are associated with trisomy 8 in approximately 35% of cases and to a lesser  
extent monosomy 7 and –Y. Mutations have been associated with K-RAS or N- 
 RAS, RUNX1, JAK2, TET2, IDH1/2 , SRSF2. PDGFR rearrangements were also  
present 
 
Juvenile chronic myeloid leukemia (JMML) 
Juvenile CMML is rare and found in children less than 14 years of age , 75%  
occurring in less than 3 years of age, it is a clonal hematopoietic disorder with  
proliferation of mainly granulocytic and monocytic lineage, total leukocytic count  
w i l l  b e  m o r e  t h a n  1 0 × 1 0 9 / L  ,  b l a s t s  a r e  m o r e  t h a n  2 0 % ,  w i t h  
monocytosis more than 100 per cu.mm. Fetal haemoglobin(HbF) is increased in  
70% of cases. Philadelphia chromosome is positive, mutations in PTPN1 have  
been found common. BCR-ABL1 fusion gene is negative. Abnormality in  
chromosome 7 is present. 
Chronic neutrophilic leukemia 
It is a rare disorder, having BCR-ABL1 fusion gene negative, commonly seen in  
the elderly. Blood picture shows marked neutrophilia with total count more than  
25×109/L , segmented neutrophils and band forms are more than 80% of  
the white cell population, immature cells like promyelocytes, myelocytes and  
metamyelocytes  are seen less than 10% of the cells, myeloblasts are less than  
1%. Mature cell pattern appear normal. Megakaryocytes can also be present.  
There is no philadelphia chromosome or the BCR-ABL1 fusion gene or any  
PDGFRA or PDGFRB or FGFR1 rearrangement seen cytogenetically. No  
evidence of any myelodysplasia or myeloproliferative neoplasm or granular  
dysplasia. Monocytes are less than 100 per cu.mm, no identifiable cause for  
neutrophilia or any evidence of infection or inflammation is seen. No other  
 tumour underlying also is seen. NAP activity is increased. Variable staining  
patterns are noticed by MPO and SBB. 
 
Chronic eosinophilic leukemia 
It is a BCR-ABL fusion gene negative chronic myeloid disease, striking  
eosinophilia is the hallmark picture. Total count can be high normal or elevated.  
Platelet counts are normal or decreased. Marrow shows myelocytic and  
eosinophilic hyperplasia, charcot leyden crystals and increased mast cell  
population. Megakaryocytes can be dysmorphic. Reticulin fibrosis is common.  
Cytogenetically translocations are common in chromosome 5 at the PDGFR gene 
site. MPO and SBB staining patterns are variable. 
 
Chronic basophilic leukemia 
It also is a BCR-ABL fusion gene negative disorder. Basophilia is striking in  
peripheral blood and marrow smears. Marrow is hypercellular with the three  
major lineages. Dysmorphic megakaryocytes are also seen. The disorder is a  
clonal myeloid disease and quite rare. Cytogenetics, do show rearrangements in  
PDGFR gene. Cytochemical stains like MPO and SBB can be variably positive. 
 
ACUTE LYMPHOBLASTIC LEUKEMIA  ALL 
Acute lymphoblastic leukemia originates in the lymphoid precursors of  
lymphopoietic stem cells of the bone marrow, lymph nodes and thymus. Almost  
75 to 80% are of B cell lineage and 15 to 20% are of T cell lineage. 
 
 ALL L 1 
This type is seen in 70 to 75% of acute lymphocytic leukemia cases. Mostly  
pediatric population are affected.The leukemic blast cells are homogenously  
uniform small cells, ranging from the same size to twice the size of small  
lymphocytes,with scanty light blue cytoplasm. The nucleus is round or slightly  
indented and has coarse chromatin or clumped chromatin and contains 1 or 2  
nucleoli. Some cases have larger blast cells. The cytoplasm in some cases have  
coarse granules which are amphophilic and found to be that of mitochondria too  
in electron microscopy.The blast cells stain positive with  Periodic Acid Schiff’s  
stain (PAS), giving a purple magenta colour, as block positivity in the cytoplasm.  
MPO and SBB are negative in these cases. PAS positive cases are usually CD10  
positive for immunomarkers. Other markers are also used  to assess the cell  
lineage , if they are from pre-B, pro-B, or T cell as well as for CALLA positivity.  
B cell lineage markers used are CD19, CD79a, and CD22, T cell markers used  
are CD3, CD7,CD34, CD117, TdT, HLA-DR and CD2 mainly. 
 
ALL L2 
In this type which is seen in almost 20 to 25% of ALL cases, the lymphoblasts  
are larger in size as well as heterogenous in nature with larger amount of  
cytoplasm. The nucleus are also varied in size, and has indentations, with  
irregular membranes, and finer to coarse chromatin, 1 or 2 nucleoli will also be  
present. Minimal cytoplasmic vacuolation can also be seen. L2 includes most of  
the adult cases and T ALL cases seen. MPO and SBB are negative while PAS  
shows block positivity. 
  
ALL L3  
This type is rare and seen in 1 to 2% of all ALL cases. The blast cells are large  
homogenous and have deep blue basophilic cytoplasm with multiple vacuoles  
overlying the nucleus. These prominent vacuolations are lipids. Blasts  
resemble that of cells in Burkitt’s lymphoma. The vacuoles stain for fat stains like  
Oil Red O positive, and are MPO and SBB negative. PAS can also be negative,  
rarely positive.Most of these cases have c MYC rearrangement.  
Morphologic correlation with FAB Sub types of Precursor B, T lymphocytic  
leukemia and Burkitt’s leukemia.3,4,19 
Precursor B lymphoblastic leukemia/lymphoma have FAB L1/L2 or Mixed  
morphology.  Precursor T lymphoblastic leukemia/lymphoma have FAB L1 or L2 or  
Mixed morphology and the cells are CD3 positive. Burkitt’s leukemia/lymphoma is  
derived from small cells which are not cleaved  and are mature B cell neoplasms. The  
blasts have FAB L3 morphology 
 
CHRONIC LYMPHOCYTIC LEUKEMIA  CLL 
This disease is heterogenous in nature and is seen in middle and old age group  
patients. It is a B Cell lymphoproliferative disorder, where CD5+ and CD23+  
mature lymphocytes are seen in blood, bone marrow and lymphoid tissues. The  
lymphocyte count is increased and is more than 20 to 200×109/L , more  
than 90% are mature lymphocytes in the peripheral blood. The leukemic blasts  
are uniform, with round nucleus and cytoplasmic rim. The nucleus has coarse  
chromatin with no nucleoli. Nuclear indentation, clefting and large atypical  
 lymphocytes will also be seen. These are associated with trisomy 12 cytogenetic  
abnormalities too. Large smudge cells are also present due to the making of the  
smear, as the cells are fragile and almost always seen in the smears. Few  
prolymphocytes are also seen. The prolymphocytes are larger with moderate  
cytoplasm, and has nucleus with coarse chromatin and a single nucleoli. Based on  
this, the FAB classification subtypes CLL as follows 
a) CLL where prolymphocytes are less than 10% 
 
b) CLL –PLL where prolymphocytes are 11-55%  
 
c) PLL where prolymphocytes are more than 55% 
80% of cases are classical CLL, and 20% are CLL/PLL or atypical CLL. Atypical  
CLL are cases which have mixed type, where there are predominant small  
lymphocytes and few large cells, which might have nucleoli. Some 15% of the  
cells show clefted or lobulated nuclei, which can be seen in trisomy 12 and other  
cytogenetic abnormalities. Red cells are usually normocytic normochromic ,  
haemoglobin can be low, erythroid elements can get diminished in the marrow as  
the disease progresses. Platelets are generally normal and thrombocytopenia is  
rare. Bone marrow is hypercellular because of lymphocytic infiltration, which is  
more than 30% and can be nodular , mixed or diffuse in infiltrating the  
interstitium. Lymphocytes in the marrow vary from 30 to 95%, there by the  
erythroid population gets diminished. In cases of associated autoimmune  
haemolytic anemia, there is erythroid hyperplasia. Megakaryocytes are normal in  
number. Rarely Red cell aplasia develops which is due to parvo B19 virus  
infection and giant sized erythroblasts can be seen. PAS stain is variable in  
nature. Immunomarkers used for B cell lineage are CD19, CD23 and CD5, which  
 are positive, CD5 being a T cell marker identifies co-expression with B cell  
lineage. CD10,CD79a and FMC7 is negative in CLL, and CD20 is seen in  
atypical CLL. Aberrant CD5 expression signifies CLL/SLL types. Small  
lymphocytic lymphoma(SLL), the blast cell in the lymph nodes, has absent  
cytopenias in peripheral blood and lymphadenopathy is the common feature.  
International workshop CLL guidelines for the diagnosis (2008).4 
 1) Clonal proliferation of abnormal B lymphocytes in peripheral blood for  
       more than 3 months. 
 2)   B lymphocytes should be atleast 5×109/L.  
 3)   Atypical / immature blast cells/ prolymphocytes should be less than 55%. 
 4)   More than 30% of lymphoid cells should occupy the bone marrow. 
 5)   Low density of surface immunoglobulin (IgM or IgD) with κ or λ light chains  
        should be present. 
 6)   B cell surface antigens ( CD19, CD20dim, CD23) is to be present. 
 7)   CD5 surface antigen is present. 
 8)   Lack of pan T cell markers other than CD5 is to be seen. 
 
Hairy cell leukemia 
It is an uncommon form of adult chronic B cell leukemia, the characteristic  
leukemic cells are found in the marrow, blood and spleen. Patients present with  
infections , fatigue and splenomegaly. Most of them have pancytopenia, due to  
impaired hematopoiesis in the infiltrated marrow and sequestrated spleen.  
Anemia , absolute neutropenia are also present.Monocytopenia is also seen.  
Morphologic presence of hairy cells, with pale blue or grey cytoplasm with  
 ruffled border, nucleus round to oval or reniform with indistinct nucleoli and  
spongy chromatin is seen. These cells are TRAP positive. Flow cytometry  
identifies the profile with immunomarkers CD2O, CD11c, CD103,CD123, and is  
negative for CD5, CD10, CD27, and CD43. BRAFV600E mutation is present and  
confirmatory. Marrow fibrosis is very common and characteristic, characteristic  
mononuclear cells with a “fried egg appearance” is also seen. 
 
CYTOCHEMICAL STAINS IN LEUKEMIA 
Despite a lot of advances in defining the diagnosis of leukemias, careful  
examination of  Romanowsky stained  peripheral blood smears and bone marrow  
smears remains the fundamental in the haematological diagnosis.10  Microscopy  
and cytology remain the gold standard in elucidating the provisional diagnosis of  
leukemias. With the advent of cytochemistry in the earlier part of the twentieth  
century, the understanding of leukemic cell morphology and its staining patterns  
ushered in new changes and challenges in confronting the disease. FAB  
Classification which came into existence in 1976, was solely based on the  
cytomorphological pattern seen in the special stains used, and helped a lot in  
understanding  leukemias in general, and depending on its classification the  
Acute and Chronic forms of the disease were well documented. Specific  
cytochemical stains have now been used to differentiate leukemic cell  
abnormalities in their nucleus and cytoplasm. Deformities in the nucleus such as  
the acquired Pelger-Huet anomaly of neutrophils,  abnormalities of  the  
cytoplasmic granules in the cytoplasm called the Auer rods or by defective  
granularity in the eosinophils have been demonstrated. Hayhoe and his co- 
 workers demonstrated the staining patterns of periodic acid schiff’s stain (PAS),   
peroxidase and the Sudan black reaction to classify the leukemic blast cells in  
lymphoblastic, myeloblastic, monoblastic and erythroblastic cells.12  This  
ancillary tool remained the gold standard until immunocytochemistry took over,  
and still continues be an handy one in diagnosing the disease, and is one among  
the components in diagnosis apart from immunophenotyping with markers and  
cytogenetics, thus giving a multifaceted approach to it. 
 
Leukocyte cytochemistry.2 
This includes techniques used to identify diagnostically useful enzymes or other  
substances in the cytoplasm of hematopoietic cells. These techniques are  
particularly useful in the identification of immature blast cells in AML and  
identification of maturation abnormalities in the myelodysplastic syndromes and  
myeloproliferative neoplasms. The use of it in characterizing lymphoproliferative  
neoplasms have been superseded by immunological techniques and therefore  
should be interpreted with Romanowsky’s stains and immunophenotyping.  
Various techniques have been employed, and recommended by an Expert Panel  
of the International Council for Standardization of Hematology, which gives the  
theoretical and practical aspects of cytochemistry. 
 
Principal uses of cytochemistry2 
1.To characterize the blast cells in acute myeloid leukemia, leading to its  
  diagnosis, unless there is evidence of lymphoid differentiation. 
2.To demonstrate the myeloperoxidase or non-specific esterase activity, thus  
    contributing to a mixed phenotype acute leukemia, according to the 2008 WHO  
   classification of tumours of Hematopoietic and Lymphoid tissues. 
3. To identify granulocytic and monocytic components of AML. 
4. To identify unusual lineages occasionally involved in clonal myeloid disorders                       
    (e.g basophils and mast cells)  
5. To detect cytoplasmic abnormalities and enzyme deficiencies in myeloid  
   disorders (e.g myeloperoxidase deficient neutrophils in myelodysplasia or acute             
    leukemia, neutrophil alkaline phosphatase deficient neutrophils in CML.  
6.To identify Auer rods in MDS and thus classify a case as refractory anemia   
    with excess of blasts II in the WHO Classification 
7. To confirm the diagnosis of Hairy cell leukemia 
List of cytochemical stains used 
1. Myeloperoxidase (MPO). 
2. Sudan Black B (SBB). 
3. Neutrophil Alkaline Phosphatase. 
4. Acid Phosphatase Reaction  including  
    Tartrate Resistant Acid Phosphatase (TRAP).    
5.Periodic Acid-schiff  Reaction (PAS). 
6. Esterases 
     Naphthol AS-D Chloroacetate Esterase (CAE) 
     α – Naphthyl Butyrate Esterase (ANBE) 
     α -  Naphthyl Acetate Esterase (ANAE)  
     Double Esterase method. 
7. Toluidine Blue. 
  
Myeloperoxidase (MPO) 
Myeloperoxidase is seen in the primary and secondary granules of neutrophils  
and their precursors, also in the eosinophils and in the azurophilic granules of  
monocytes. The MPO in eosinophil granules is cyanide resistant , where as that in  
the neutrophils and monocytes is sensitive. MPO splits H2O2 and in the presence  
of chromogenic electron donor and forms an insoluble product. DAB (3,3/ - 
diaminobenzidine) is the preferred chromogen used here. The reaction product is  
stable, insoluble and non-diffusable too. MPO is not inhibited by heparin, oxalate  
or EDTA anticoagulants. Staining is done in room temperature, which remains  
satisfactorily for a week. DAB should be in frozen temperature storage, kept at     
-20oC . Optimum results can be obtained with good DAB buffer mixture and  
adjustment of counterstaining time with hematoxylin to give good nuclear details.  
Results and interpretation 
The results of the staining product, show a brown and granular Red cells, and  
erythroid precursors show diffuse brown cytoplasmic staining. The most early  
primitive myeloblasts are negative, but granular positive appears as they progress  
to the promyelocytic stage. Positivity is seen in the Golgi region. Promyelocytes  
and myelocytes are strongly positive, as the positive primary granules are present  
in the cytoplasm. Metamyelocytes and neutrophils have lesser secondary granules  
and are progressively fewer positive. Eosinophils granules stain strongly and the  
larger granules are easily distinguished from the neutrophil granules, as the  
peroxidase is distinctly different both biochemically and immunologically in  
it. Monoblasts and monocytes can be positive or negative, and when seen  
 positive, they lie scattered in the cytoplasm of the cells. MPO activity is seen  
basophil granules but not in mature basophils. Individuals with congenital  
deficiency of neutrophil MPO show negative in the neutrophilic lineage, but  
eosinophils stain normally. Dysplastic neutrophils may show negative staining  
pattern. Auer rods stain positive and are seen well with DAB, than with the  
Romanowsky’s stains. 3% of blasts in the stained smears is the cut off point.7 
 
Sudan Black B (SBB) 
Sudan Black B is a lipohilic dye that binds irreversibly to the granular component  
in the granulocytes, eosinophils and some monocytes. This gives almost the same  
information as that of the MPO staining pattern. Here the fixative used is  
formalin vapour for the smears. Alternative fixative used is formal acetone. The  
working staining solution is to be replaced after four weeks. Marrow smears  
which have lipid soluble SBB, can be rinsed for 5 seconds in xylene prior to  
counterstaining with May-Grunwald Giemsa or Leishman stains. Thereby the  
cytological detail is seen well with it.  
 
Results and interpretation 
The reaction product is black and granular. The results are similar to MPO  
staining, both in leukemic cells and normal cells. MPO negative neutrophils are  
also negative for SBB. Eosinophils give a clear core in their granules when  
stained with SBB, which is not seen in MPO. Rare cases of ALL can show non- 
granular smudgy positive reactions which is not seen in MPO staining. Basophils  
show bright red or purple metachromatic granules. More than 3% of positive  
blasts is the cut off point for the diagnosis.7 
  
Neutrophil Alkaline Phosphatase (NAP) 
Neutrophils contain Alkaline phosphatise activity. It can also be seen in  
metamyelocytes. It is demonstrated as a granular product in the cytoplasm, the  
enzyme activity is associated with intracytoplasmic membranous component,  
distinct from primary and secondary granules. Some cases of  lymphoid  
malignancies do show positive activity. Bone marrow macrophages also show  
positivity. Azo dye techniques, using substituted naphthols as the substrate, and  
its ensuing action in liberating naphthol , to combine with the azo dye, a fast blue,  
gives an insoluble precipitate at the site of enzyme activity, which is read as  
positive. Formal methanol fixatives are used for smears, Naphthol AS is the  
substrate used and Fast blue the azo dye mixed in the working solution.  
Counterstain used is neutral red. Glass tubes are used for substrate, as plastics can  
get dissolved with formamide. Blood smears should be done as early as possible  
within 30 minutes of collection, as EDTA anticoagulant can reduce NAP activity,  
and should be stained within 6 hours. Control films also are to be used.  
Results and interpretation 
The positive smears show blue and granular. Intensity is noted from negative to  
positive in the reaction product of neutrophils, with coarse granules filling the  
cytoplasm and overlying the nucleus. Score is obtained by assessing the intensity  
in 100 neutrophils consecutively, with each scored on a scale of 1 to 4. 
 0 – negative or no granules 
1 – occasional granules scattered in cytoplasm 
2 – moderate number of granules 
 3 – numerous granules 
4 – heavy positivity with numerous coarse granules in the cytoplasm and             
      overlying the nucleus. 
Score ranges from 0 to 400 in 100 assessed neutrophils.Each laboratory has its 
established scoring done.Normal individuals usually do not have a score of  3 and  4 . 
New born babies, pregnant women and children have high scores. Perimenopausal 
women do have a score one third higher than men. Significant low score is seen in 
CML, which is diagnostic of use, especially in the chronic  phase, where it is usually 
zero. In accelerated phase, and in myeloid  transformation, the score rises. Moderate 
rise is seen in intercurrent infection.  Low scores are seen in paroxysmal nocturnal 
hemoglobinuria (PNH), and  hereditary hypophosphatasia. Raised scores are seen in 
neutrophilia of infection,  leukemoid reaction, and Hodgkin’s lymphoma. In aplastic 
anemia, the score is  high and can get low once PNH sets in. 
Acid phosphatase reaction including Tartrate Resistant Acid Phosphatase  
Reaction (TRAP) 
The main use of this cytochemical stain is in the diagnosis of  T- cell ALL and  
Hairy cell leukemia. The pararosaniline method is commonly employed , and is  
used for the demonstration of the positivity in the T-cells. Fast Garnet as a  
coupler in the reaction demonstrates the tartrate resistant acid phosphatase  
activity. Methanol, acetone and citric acid are used as fixatives, before staining.  
Naphthol AS-BI phosphate is used as the substrate, dissolved in N,N- 
dimethylformamide. The coupler agent used is the pararosaniline. The working  
solution is made up of  Michaeli’s veronal buffer, with naphthol substrate, and  
 hexazotized pararosaniline and tartaric acid. Smears are stained by incubating in  
the working staining solution for 1 hour and counterstained with methyl green or  
hematoxylin. 
Results and interpretation  
The Acid phosphatase enzyme present in the cell, will be inhibited by the tartrate,  
and no colour is seen, where as in hairy cell leukemic cells, they are not inhibited,  
and a precipitate red colour is seen as positivity in the cytoplasmic granules. They  
can be diffuse positivity too. Almost all T-cell lineage show strong positivity. In  
T-cell ALL, the positivity is highly polar. Granulocytes also show positivity, so  
do macrophages, plasma cells and megakaryocytes in the bone marrow. In hairy  
cell leukemia, almost all leukemic cells, are positive in the absence or presence of  
tartrate . Though immunophenotyping methods are more reliable, the TRAP stain  
method is more useful, when they are not available. 
 
Periodic Acid–Schiff  Reaction (PAS) 
It is one of the main stains used for identifying  Acute lymphoblastic leukemias,  
the stain indicates the presence of glycoproteins, mucoproteins, and high  
molecular weight carbohydrates in blood cells. Periodic acid oxidizes the glycol  
groups to produce aldehydes. When these are exposed to schiff’s reagent, which  
is leuco basic fuchsin, they produce a magenta red colour in the granules or  
cytoplasm. The reaction occurs positively with glycogen, monosaccharides,  
polysaccharides, glycoproteins, mucoproteins, phosphorylated sugars, inositol  
derivatives, and cerebrosides. Glycogen is sensitive to diastase digestion and  
this distinguishes it from other positively reacting substances. In blood cells the  
 main source of positive reaction is glycogen. The fixative used is methanol,the  
periodic acid and schiff’s reagent are used for staining, and the counterstain used  
is hematoxylin. Other fixatives used are formal vapour and formal acetone.  
Previously fixed, iron stained or Romanowsky’s stained films can be overstained  
with PAS reaction well. Romanowsky’s stained smears can be dipped in  
methanol before the staining process to partly decolourize the smear. The  
intensity of the colouration depends on the quality of the schiff’s reagent. Normal  
neutrophils stain red, deterioration in the Schiff reagent can be detected by seeing  
control smears. Sodium metabisulphite can be used, with schiff’s reagent, but  
does not require often. 
 
Results and Interpretation 
The stain produces a magenta red colour, with intensity ranging from pink to  
bright red. Cytoplasmic positivity is either diffuse of granular. The granulocyte  
precursors show diffuse weak positivity, neutrophils show strong granular  
positivity. Eosinophils show granular negativity, but diffuse cytoplasmic  
positivity. Basophils may be negative, but often show block positivity, not related  
to the granules. Monocytes and their precursors show variable diffuse staining  
positivity, seen at the periphery of the cytoplasm. Normal erythroid cells and its  
precursors stain negative. Megakaryocytes and platelets show variable intense  
diffuse positivity, with the granules being superimposed.  Granular positivity  
with cytoplasmic negativity is seen in 10 to 40% of peripheral lymphocytes.  
lymphoblasts show block positive cytoplasmic granules, and can be variable too.  
Block positive lymphoblasts clearly differentiates it from myeloblasts, which are  
 negative. Cytoplasmic blush is seen in acute promyelocytic leukemia, and in M7  
of acute myeloid leukemia, it shows granular positivity in the megakaryocytic  
type. M6 of AML can also show granular block positive. Abnormal erythroblasts  
give coarse granular positivity and dysplastic megakaryocytes in MDS can give  
diffuse cytoplasmic positivity with coarse granules. More than 5% of stained  
blasts in the smears is the cut off point for positivity, less than it is considered  
negative.9,21  
 
Esterases  
Naphthol AS-D Chloroacetate esterase (CAE) 
Neutrophils have the specific esterase, and they are isoenzymes in the group band  
1,2,7,8,and 9 and stain specifically with CAE. Fixatives used is the buffered  
formal acetone with Naphthol AS-D chloracetate as the working solution,  
coupling agent is the hexazotized new fuchsin and sodium nitrate, with the  
counterstain used being hematoxylin. Fast blue is also used instead of fuchsin,  
Here incubation of slides is important, as more the time if given, scattered  
granular staining  occurs, hydrolysis is rapid and the staining time is usually over  
within 3 to 5 minutes.  
 
Results and interpretation 
Staining causes a bright red colouration, confined to the cells of the neutrophilic  
series and the mast cells. Cytoplasmic positivity is seen in promyelocytes amd  
myelocytes. Hence it is useful in staining smears of  Acute promyelocytic  
leukemia. Auer rods take up the stain positively. 
  
α – Naphthyl Butyrate esterase (ANBE) – Non specific esterase 
Bands 3,4,5, and 6, of the isoenzymes of the esterase correspond to this enzyme.  
Fixative used is the formal acetone, buffer used is the Sorenson’s phosphate  
buffer, substrate is the alpha naphthyl butyrate, coupling agent used is fast garnet  
and the counterstain employed is hematoxylin. Here the slides are mounted in  
gum arabic mountant or glycerine, as the reactant product is soluble in immersion  
oil and synthetic mounting media. Staining is complete when dark brown colour  
appears, which is checked at incubation period. Pararosaniline is another coupling  
agent which can be used, and is insoluble , so a synthetic mounting media can be  
used. 
 
Results and interpretations 
The positive reaction is a brown colour seen in majority of monocytes, over 80%  
of them stain positively. Neutrophils, basophils, eosinophils and platelets are  
negative. B lymphocytes are negative, where as T lymphocytes stain variably. In  
the marrow monocyte and its precursors as well as macrophages stain positively.  
ANBE is more specific for identifying the monocytic component in AML. 
α – Naphthyl Acetate Esterase (ANAE) 
This also is a non specific esterase,  the fixative used is buffered formal acetone,  
substrate is alpha naphthyl acetate, phosphate buffer is used and the coupling  
agent used is the hexazotized pararosaniline with sodium nitrate,and counterstain  
being hematoxylin. Fast blue can also be used as a coupling agent. The substrate  
solution is soluble in mounting media, glycerine hence ,is used for mounting.  
 Results and interpretation  
The staining reaction is diffuse red to brown in colour. Monocytes stain strongly  
as well as the leukemic cell. Granulocytes stain negative, but in MDS or AML  
can give positive reactions with variable staining. Megakaryocytes and  its  
leukemic cells stain strong diffuse positive, and also focal too. T lymphocytes and  
lymphoblasts show focal dot like positivity. Leukemic erythroblasts also show  
focal positivity. 
 
Combined esterase stain ( ANAE and CAE) 
The staining protocol is similar as in ANAE , Fast blue is used as the coupling  
agent here, naphthol AS-D chloroacetate is mixed in the working medium for  
incubat ing the  s l ides ,  and hematoxyl in  i s  used as  the  counters ta in . 
 
Results and interpretation 
The staining product is a brown colour and the CAE gives a bright blue colour to  
the granules. This can be used in acute myelomonocytic leukemias, MDS and in  
AML with dysplastic granules. 
 
Double esterase method 
Both ANAE and ANBE substrates are used here, the coupling agent is the Fast  
blue, phosphate buffer is used, and formal acetone is the fixative for the smears.  
Timing of staining can be extended upto 30 minutes in order to have maximal  
staining with ANBE. 
  
 Results and interpretation 
The CAE stains bright blue in the granulocytes, and the ANBE stains dark green  
to brown in monocytes. ANBE does not stain megakaryocytes or T cells as much  
as the CAE stain. It is useful for identifying monocytic and granulocytic cell  
components. 
 
Toluidine Blue 
This stain is useful for basophil and mast cell identification and for its  
enumeration. It binds strongly to the granules and is helpful in AML as well as  
CML and other myeloproliferative neoplasms. 1% toluidine blue in methanol is  
the staining substrate used. 
 
Results and interpretations  
Basophil and mast cell granules are stained bright red to purple and are very  
much distinct and discrete. Nuclei stains blue in colour and cells having abundant   
RNA can show a bluish tint in the cytoplasm. If staining period is kept for more  
than 10 minutes, the granules of the promyelocytes also take up the colour. These  
granules are smaller compared to those of the basophils and mast cells.  
 
Cytochemical reactions in MDS 
MDS shows a variety of  morphological  abnormali t ies,  the marrow is  
hypercellular, and has peripheral cytopenias can be identified. Perl’s reaction  
identifies ring sideroblasts, other cytochemical evidence of dysplasia are  
identified by the double staining of cells with ANAE and chloroacetate,  
 neutrophils show SBB or MPO negativity, but Auer rods can be identified with  
them. ANAE and ANBE are useful in identifying the monocytic cells in AML, as  
well as demonstrating Auer rods and dysplasia. 
 
Differences between myeloblast and lymphoblast based on morphology and 
cytochemistry.4  
 
 
 
 Lymphoblast 
 
Myeloblast 
 Size 2 to 3times the size of 
lymphocyte 
3 to 5 times the size of 
lymphocyte 
Cytoplasmic 
characteristics 
  
   Amount Scanty, lesser than 
myeloblast 
Scanty to moderate, more 
cytoplasm than lymphoblast 
   Colour Blue Gray 
   Cytoplasmic granules Agranular May contain granules 
   Auer rod Negative  Positive  
Nuclear characters   
  Nuclear chromatin Uniform, coarse Uniform, fine 
  Nucleoli Inconspicuous or 1 to 2 3 to 5, prominent 
  N:C Ratio High  High  
Accompanying cells Lymphocytes  Promyelocytes, myelocytes, 
metamyelocytes, band 
forms and neutrophils 
Cytochemistry    
 Myeloperoxidase  Negative  Positive  
 Sudan Black B Negative Positive  
 PAS Block positive Negative  
 Non-specific esterase Negative  Positive in M4 and M5 
     
CYTOCHEMICAL STAINS  USEFUL  IN  TYPING THE BLAST CELLS 
 
STAIN Precursor B-
ALL 
Precursor T-
ALL 
AML 
M1-M3 
AML 
M4-M5 
AML 
M6-M7 
Myeloperoxidase  Negative  Negative  Positive  Positive  Negative  
Sudan Black B Negative  Negative  Positive  Positive  Negative  
PAS Positive 
(coarse) 
Negative  Negative  Positive  Positive  
(fine) 
Non specific 
esterase 
Negative  Negative  Negative  Positive  Positive  
(focal) 
Acid phosphatase Negative  Positive  
(focal) 
Negative  Positive  
(diffuse) 
Positive  
(focal) 
 
  
 Immunophenotyping.1,2,3 
Immunophenotyping have revolutionised the methods of diagnosing leukemias,  
and today is the gold standard in its diagnosis and management . A multifaceted  
approach has evolved, including basic cytology, cytochemical study pattern,  
along with immunophenotyping and cytogenetics in the current setting of therapy  
and prognosis.19  The WHO classification emphasizes the importance of  
immunophenotyping, and defined the antigenic nature of the neoplastic cells in  
myeloid and lymphoid malignancies.11 This technique uses the identification of  
antigens on hematopoietic cells, which are lineage specific and are restricted to  
particular level of differentiation in it. Detection of cytoplasmic and nuclear  
antigens, usage of multicolour immunostaining with labelled monoclonal  
antibodies, quantification of the number of molecules of an antigen as well as  
analysis of selected population of cells by the estimation of gating methods, are  
the main technical derivatives of immunophenotyping.  Flow cytometry is the  
technique used for immunophenotyping. A lot of  improvements in the  
instrumentation have been done and Multicolour f low cytometry, with  
multiparametric immunophenotyping have facilitated accurate identification of  
normal and abnormal cell populations. This has provided a comprehensive  
knowledge of the data obtained and interpreted.  Assignment of lineage detecting  
panels, like the lymphoid panel and the myeloid panel of markers is important,  
and used in most laboratories. There is an abundance of monoclonal and  
polyclonal antibodies, to assess the myeloid and lymphoid lineage by flow  
cytometry. The blood and bone marrow samples are commonly employed,  and  
the natural fluid suspension helps a great deal in its assessment. Flow cytometers  
 use the principle of light scatter and flouresence with flourochromes to define the  
cellular population, by tagging with antibodies. The cell suspension is passed on  
the laminar flow, which passes through a laser beam. The scattered light and  
fluorescent emitted light data are collected after appropriate filtration by the  
photomultiplier tubes. Here the light scatter information is collected at 90 degree  
angle, which correlates with cytoplasmic granularity and nuclear complexity.  
This helps in differentiating between myeloid progenitors, monocytes, and  
mature granulocytes from lymphoid cells and blasts. The primary requirement  
here is that the cells should be viable in a suspension prior to staining. Most of  
the  Flow cytometric methods, use a four to six colour analysis, and even three, to  
detect the side and forward light scatter for routine panels. Following washing  
and lysis of red cells, direct addition of monoclonal antibodies is done to analyse  
the cell surface proteins. Assessment of intracytoplasmic and nuclear associated  
proteins is accomplished after staining for surface markers, and fixing the cells,  
and adding relevant antibodies to the cell suspension with a membrane permeable  
agent. Gating is important to have the relevant cell population under study,  
especially in heterogenous samples like bone marrow, where the studied  
population is less in overall. Here the cells at the front end selection of the flow  
cytometry use a CD45antigen and 90 degree light scatter to distinguish the blast  
cells from the normal cells in the population. The back end has the fluorescent  
markers. The blast gate helps to identify the cells with specific markers. Care is  
taken for unusal light scatters, to make sure abnormal cells are not hiding. 
  
 Indications for flow cytometry.3 
Indications include mainly the evaluation of haematological malignancies. 
 1.Diagnosis and classification of hematopoietic neoplasms. 
 2. Used for the prognostic significance of the neoplasm. 
 3. To identify potential therapeutic targets in the haematological neoplasms. 
 4. To monitor response to therapy, by looking for minimal residual disease.          
 5. To evaluate the adequacy of  blood stem cell collection.      
Data analysis and reporting            
Analysis of the data received for the equipment uses a sophisticated computer and  
programme devised to perform compensation, two dimensional histograms for  
two parameter dot plots or scatter plots, to identify the abnormal cell population  
and enumerate the various cell populations for study. After the gating strategies,  
to exclude all non-viable cells to delineate the population for study, the antigenic  
abnormalities are observed. The histogram plots forward light scattering to side  
light scattering in a diagrammatic graphic colour representation, which helps in  
identifying the phenotype, the proportion of abnormal cells to the total viable  
cells is described in a free text format. 
Cell type and antigens detected by monoclonal antibodies  
Cell type Antigen designation 
T cell CD1, CD3, CD4, CD5, CD8 
B cell CD10, CD19, CD20, CD21, CD23, CD79a 
Monocyte or Macrophage CD11c, CD13, CD14, CD15, CD33, CD64 
Stem cell and progenitor cell CD34 
All leukocytes CD45 Leukocyte common antigen 
NK cell CD16, CD56 
 
 Immunological markers used in the panels for diagnosis.1,2,3 
AML panels 
    First line panel used are CD13, CD33, CD117, anti-MPO. 
    Second line panel used CD41, CD 42, CD62p, anti glycophorin A (CD235a). 
    Optional markers like CD14, antilysozyme, CD36 and CD64 are used for    
    Identifying  monocytic component. 
 Phenotypes and markers positive for AML 
Myeloblastic CD11b, CD13, CD15, CD33, 
CD117,HLA-DR 
Myelomonocytic CD11b,CD13, CD14, CD15, CD32, 
CD33, HLA-DR 
Erythroid Glycophorin,spectrin, ABH antigens, 
carbonic anhydrase I, HLA-DR, CD71 
Promyelocytic CD13, CD33 
Monocytic CD11b, CD11c, CD13, CD14, CD33, 
CD65, HLA-DR 
Megakaryoblastic CD34, CD41,CD42, CD61, anti- von 
Willebrand factor 
Basophilic  CD11b, CD13, CD33, CD123, CD203c 
Mast cell CD13, CD33, CD117 
 
ALL panels  
B Cell lineage 
First line panels used are CD19, CD22, CD79a, CD10a, CD20. 
Second line panels used are cµ and SmIg. 
CD11c, CD25, CD103, CD123, CD38, CD138, cIg are also used. 
CD10 and cµ are useful in pediatric cases to identify common –ALL (CALLA),  
pro-B-ALL, and pre-B-ALL. 
 
 T Cell lineage  
First line panels used are CD7, CD2, cCD3, TdT, HLA-DR, CD34. 
Second line panels used are CD1a, CD5, CD4, CD8, anti-TCR. 
   
CLL panels  
B Cell lineage 
First line panels used are SmIg(kappa/lambda), CD19, CD23, FMC7, SmCD79b,  
SmCD22, CD5a,CD20b.  
Second line panels used are CD11c, CD25, CD103, CD123, CD38, CD138, cIg. 
T Cell lineage  
First line panels used are CD2, CD5a. 
Second line panels used are CD3, CD4, CD7, CD8, CD57. 
CML panels  
Panels used here included CD3, CD10, CD11c,CD13, CD19, CD33, CD41a, and  
CD45. CD7 expression is seen myeloid and undifferentiated blast crisis, and  
CD34 is seen in lymphoid blast crisis and myeloid blast crisis. CD203c, gives an  
accurate assessment of the Basophils and its frequency. CD56 detects NK cells,  
they are very much reduced in CML. CD45 and CD45RO is expressed in CML.  
CD45RA is not expressed, and helps to differentiate from AML. The fusion gene  
identification of  BCR-ABL1 by FISH technique, and the identification of the  
Philadelphia chromosome(22q-),  is the hallmark for the diagnosis and  
constituting therapy. 
  
 Clinical features of leukemia.1,4,5 
AML 
Predominantly seen in younger age individuals more than 25 years of age, the  
general symptoms and signs encountered usually are Pallor, fatigue, weakness,  
palpitations, and dyspnea. Bleeding tendencies due to thrombocytopenia can also  
manifest as, easy bruisability, petechiae, epistaxis, gingival bleeding, and  
bleeding from GI tract, genitourinary tract, pulmonary or CNS bleeding. Pustules  
and minor skin infections can also occur, major infections of the lung, CNS, and  
pneumonia, as well as pyelonephritis are uncommon. Post chemotherapy can lead  
to severe infections due to neutropenia. Anorexia and weight loss can also be  
present. Splenomegaly and hepatomegaly does occur in a quarter of cases.  
Lymph node enlargement is also uncommon.Meningeal involvement is common  
in the monocytic type. Myeloid sarcomas are associated, and seen as an  
extramedullary mass, in areas of skin, orbit,sinuses, bone,chest wall, breast,   
spleen, lymph nodes, urinary tract, gastrointestinal tract, respiratory tract, and  
CNS. Marrow expansion causing bone pain also can be seen. Leukostasis is  
common as the blasts are larger in size, and expresses adhesive proteins. This can  
lead to cerebral leukostasis causing headache,confusion and visual disturbances.  
Pulmonary leukostasis can cause dyspnea at rest. Gingival hypertrophy is  
common in M4 and M5 cases, as cellular extravasation is seen. Disseminated  
intravascular coagulation and primary fibrinolysis is commonly seen in M3 cases.  
Tumour lysis syndrome can occur leading to variety of metabolic derangements. 
 
 
 CML 
It is seen more, above the ages of 50 and 60, they have a gradual onset, most of  
them are diagnosed incidentally, pallor  due to anemia and hypermetabolism due  
to rapid turn over of cells is seen, fatigue, weight loss, anorexia is seen. Massive  
splenomegaly is common, which is due to extramedullary hematopoiesis, causing  
a  ful lness  in  abdomen.  Sternal  tenderness ,  bone pain  are  a lso  seen.  
Lymphadenopathy if present, indicates the progression from accelerated phase to  
blast crisis. Bleeding tendencies are rarely seen, if present can have retinal  
haemorrhages, causing visual disturbances.Venous thrombosis is rare, leukostasis  
causing symptoms like dyspnea, drowsiness, confusion, priapism are rare and is  
seen in accelerated and blast phases. Gouty arthritis due to high turn over of  
leukemic cells can also be present. 
 
ALL  
It is predominantly seen in children between 1 to 5 years of age, and also be seen  
in adolescent and adults too, also commonly seen in older patients above 65 years  
of age. Symptoms can present insidiously or can be acute in presentation. Fever is  
a common symptom, caused by the presence of neutropenia, producing  
infections, and the leukemic cells producing a variety of cytokines. Fatigue and  
lethargy are also seen. Anemia and pallor can be seen in older individuals,  
presenting as dyspnea. Bone pain and arthralgia are common in children,  
presenting with limping walk, due to the leukemic infiltration into the  
periosteum, bone and joints, as well as due to the marrow expansion. Some can  
have marrow necrosis. Less common symptoms include, vomiting, headache,  
 altered sensorium, oliguria and anuria. Occasionally , hepatosplenomegaly can be  
seen, especially more in children. Leukemic meningitis can also present. Gingival  
hypertrophy, coagulopathy are not seen here. Leukostasis is rare. Lymph nodes  
can be enlarged also. Rare cases of intra cranial bleed have been reported.  
Leukemic infiltration in skin, causing petechiae, and ecchymosis, are present.  
Extramedullary involvement in the liver, spleen, lymph nodes, testes,  
mediastinum, orbit, iris, retina,cornea, conjunctiva, subcutaneous tissues, salivary  
glands,and cranial nerves are also seen. Priapism due to leukostasis of the corpora  
can also be a feature. Epidural spinal cord compression is rare. Tonsils, adenoids,  
appendix, and mesenteric nodes can get infiltrated, especially in children. 
 
CLL  
CLL is seen in older age group, above the age of 65. Most of them present as  
asymptomatic ones, on diagnosis. Mild fatigue, with limitations in daily activity  
can be seen. Night sweats, fever, weight loss, pallor related to anemia,  
l ymphadenopath y,  sp l enomega l y a re  a l so  seen .  H ype rsp len ism and  
thrombocytopenia can be found too.Hepatomegaly, because of liver infiltration is  
unusual. Advanced disease can result in multiple organ involvement. Pulmonary  
infiltration is also seen due to infiltration in the interstitium. Chylous pleural  
effusion can occur. Gastrointestinal mucosal infiltration causing iron deficiency  
anemia, chronic diarrhoea, and malabsorption can be present. Involvement of the  
CNS is rare, and can present with meningeal signs as well as cranial palsies.  
Moreover these patients can have opportunistic infections, in the central nervous  
system due deficient immune system. Insect bite hypersensitivity is also present  
 with painful eruptions and erythematous lesions, which is due to skin infiltration  
of the leukemic cells. Tumour lysis syndrome also can occur. 
 
Laboratory  haematological features. 1,3 
AML 
Anemia is a common feature and hemoglobin values fall drastically in the course  
of the disease. Values are seen below 8gm/dl commonly. Reticulocyte count is  
between 0.5 to 2.0%. Red cell morphology can varied to dimorphic in picture,  
with poikulocytosis. Nucleated red cells can also be seen. Thrombocytopenia is  
common and values of platelet count are below 50×109/L. Giant platelets and  
granulated platelets can also been. The total leucocyte count is initially less than  
5×109/L , and gradually raises to above 50×109/L. The absolute neutrophil count  
is initially lower than 1×109/L, gradually becoming normal or more. Neutrophils  
can be hypo or hypersegmented and hypogranular. Peripheral smears show  
myeloblasts with mixture of immature blasts, promyelocytes and with Auer rods  
in the cytoplasm. Faggot cells having bundles of Auer rods can also be present.  
Marrow shows upto 95% leukemic blasts, more than 20% of blast is the WHO  
cut off value. Leukemic blasts give positive reaction to MPO, SBB,and  
Chloroacetate esterase stains. Flow cytometric analysis using the myeloid panel  
of markers, can be diagnosed as per the criteria. Cytogenetics determine the  
aneuploidy  and  pseudoploidy  of the cases. 
 
  
 CML 
Hemoglobin values are markedly reduced. Red cells show variations in size and  
shape,with elliptocytes, and a few nucleated cells. The reticulocyte count is  
normal or slightly raised. The total leucocytic count, is markedly raised, and is  
mostly seen above 25×109/L. All stages of development of the granulocytes are  
seen in the smears.In the chronic phase, there is mild anemia,the platelet count is  
usually normal or elevated, can go upto 1000×109/L, The serum Lactic acid  
dehydrogenase levels as well as serum uric acid levels are raised. Marrow shows  
hypercellularity, with blasts less than 5%, with classical morphology. Accelerated  
phase shows, increased basophils, more than 20%, peripheral blood blasts show  
more than 10% upto 19% blast cells, increasing total count, and the platelet count  
is low, falling below 100×109/L, or can be high, going as high as upto  
1000×109/L. Basophils are more than 20%. In the blast phase, the blasts are more  
than 20%, extramedullary proliferation of blasts are seen, marrow show  
aggregates of myeloid blasts, but in 20 to 30% cases lymphoid blasts are also  
seen, mixed lineage can be found. Cytogenetic analysis to identify the  
Philadelphia chromosome,by FISH techniques, as well as to identify the BCR- 
ABL fusion gene is also done. 
 
ALL 
Cytomorphology of the blasts can be identified by Romanowsky’s stained  
smears, and the special staining with PAS, gives the block positivity feature in  
the smears. Anemia is a common feature, with falling Hemoglobin values, less  
than 8gm/dl. Neutropenia, can be seen, as also thrombocytopenia, in newly  
 diagnosed cases. Platelet counts, can be less than 50×109/L, and in some can be  
more than 100×109/L. The total leucocyte count can vary, as much as from 0.1 to  
1500×109/L.  Hyperleucocytosis can be seen in most of T-cell ALL cases, and  
values can be more than 100×109/L. Marked neutropenia is seen, in almost 40%  
of cases, and is associated with risk of infections, values can be low and less than  
0.5×109/L. Pancytopenia, followed by a recovering state, can be seen preceding  
the diagnosis of ALL. Serum lactic dehydrogenase levels can be raised. An  
hypereosinophilic picture can also be present in cases preceding the diagnosis.  
Serum uric acid levels also can be raised due to large leukemic cell burden and  
purine catabolism. Infiltration of the kidneys, can present with raised creatinine  
levels too. Disseminated intravascular coagulation, hypercalcemia, and liver  
dysfunction, can be seen in adolescent age group of cases of B-cell ALL, mainly  
the t(17;19)(q22;p13.3) with E2A-HLF fusion abnormality. Examination of  
Cerebro-spinal fluid , can reveal blasts in it, and is commonly seen, with at least 5  
blasts per/µL, and reveals Central nervous system involvement. ALL panels  
identify the gated blasts and are confirmatory in the evaluation of the disease,  
using flow cytometry. They help in identifying the lineage and the precursors.  
Cytogenetics determine the ploidy status, hyperdiploidy is mostly seen in  
children and hypodiploidy in adults, FISH, RT-PCR, and flow cytometric  
methods are used. Micro-array based genomic analysis of gene expression,  
identifies specific genetic alterations. 
 
  
 CLL  
Smears show the typical blast picture with smudge cells in Romanowsky’s stains.  
Anemia is a feature, with fall in haemoglobin values, the red cells are normocytic  
and normochromic,  platelets  can be normal or can have an associated  
thrombocytopenic picture. Lymphocytosis is sustained, and the values can be  
more than 5×109/L. Atypical immature lymphocytes are seen as more than 55%  
can be present. Marrow can show more than 30% of the lymphoid cells, decrease  
in red cell precursors and megakaryocytes. Panel of CLL markers in flow  
cytometry, establishes the lineage. Karyotypic analysis, using FISH, evaluates the  
abnormalities in the study, and evolution of their clonal extent. Cases with  
macrocytic anemia, should be evaluated for Coomb’s test, haptoglobin test, and  
r e t i c u l o c yt i c  c o u n t ,  t o  r u l e  o u t  a u t o - i m mu n e  h a e m o l y t i c  a n e mi a .  
Hypogammaglobinemia is a feature, as there is reduced immunoglobulins.  
paraproteinemia can also be seen, identified by light chain electrophoresis. Heavy  
chain disease, can also result in cases of CLL. 
 
 
 
 
 
 
 
 
 
  
OBSERVATION AND RESULTS 
The present study comprised of 56 cases of suspected Leukemia, taken from the  
department of pathology, Thanjavur Medical college, between January 2015  
and June 2016. The observations and the results deduced were as follows. 
Table 1                 
Age Distribution of patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AGE IN 
YEARS 
No. of Cases              % 
≤ 10 10 18 
 11-20. 12 21 
21-30 7 12 
31-40 12 21 
41-50 8 14 
51-60 2 4 
61-70 2 4 
71-80 2 4 
> 81 1 2 
TOTAL 56 
 
  
The cases were in the range of 1 to 93 years. Table1, shows the age distribution, 
with the majority of the percentage lying in the age group 11 to 20 years, and 31 
to 40 years, each having 12 cases in the category, which was found to be 21%. 
This was followed by the age group less than 10 years, with 10 cases, which 
was 18%, and 41 to 50 years group with 8 cases having 14%, closely followed 
by the 21 to 30 years group,with 7 cases, amounting to 12%.
 
 
21%
14%
Age Group and Percentage
 
 
 
18%
21%
12%
4%
4% 4% 2%
1 2 3 4 5 6 7 8 9
 
 
 
 
 
 
 Table 2 
                            Age Distribution of leukemia cases
Age in 
Years 
NO. OF PATIENTS
ALL 
Nos. %
1-20. 11 92%
21-40 1 8%
41-60 0 0%
61-80 0 0%
>80  0 0%
 
Table 2 shows, the age distribution for the diagnosed cases, where ALL is 
common in the age group of 1 to 20, with a percentage of 92. Followed by 
AML, in the same age group with 42%, and as much as 33% in the 21 to 40 age 
group. CML, was common in the age group 21 to 40, with 62%, and 25% 
presenting in the 41 to 60 age group
presentation in both 41 to 60 and 61 to 80 groups, and  had almost 34%, in 
the 21 to 40 group. 
 
 
 
AML CML 
 Nos. % Nos. % 
 10 42% 0 0% 
 8 33% 10 62% 
 5 21% 4 25% 
 0 0% 2 13% 
 1 4% 0 0% 
. CLL, had an equal percentage of 
CLL 
Nos. % 
0 0 
1 34% 
1 33% 
1 33% 
0 0% 
 
 
 
 
 
 
 
 Table 3   
                                           Sex Distribution of Cases
SEX 
ALL 
Nos. %
MALE 8 67%
FEMALE 4 33%
 
TOTAL MALE CASES – 27 
TOTAL FEMALE CASES 
The total Male cases in AML, was 10 in number, and Females were 14, 
accounting to 42%  and 58% respectively. The total Male cases in ALL, were 8, 
and females were 4, with a 67% and 33% respectively.
 
 
 
 
 
AML CML 
 Nos. % Nos. % 
 10 42% 8 47% 
 14 58% 9 53% 
– 48% 
– 29 – 52% 
 
CLL 
Nos. % 
1 33% 
2 67% 
 
 
 
 Table 4 
Distribution of patients according to types and sub types of leukemia 
 
 
TYPES AND SUBTYPES OF 
LEUKEMIA 
 
NO. OF CASES AND 
PERCENTAGE (%) 
 
AML (n=24) NO. OF CASES PERCENTAGE 
(%) 
M0 2   8 
M1 6   25 
M2 13   55 
M3 1    4 
M4 2    8 
M5 M6 M7 0 0 
ALL  (n= 12)   
L1 6   50 
L2 6    50 
L3 0 0 
CML  (n=17)   
Chronic phase 9   52 
Accelerated phase 3  18 
Blast crisis 3   18 
Chronic Neutrophilic leukemia(CNL) 1   6 
Juvenile CML 1   6 
CLL  (n=3) 3   100 
 
This table depicts the distributive nature of the different types and subtypes of  
leukemia. Of the total 56 cases, AML, with 24 cases(43%), was the highest,  
followed by CML with 17 cases(30%), ALL with 12 cases(22%) and CLL with  
3 cases(5%), was the least. In AML, 13 cases were of M2(55%), followed by  
M1, which had 6 cases(25%). In ALL, 6 cases were seen, each in L1 and L2,  
50% equally distributed. CML, had 9 cases(52%) in the chronic phase, which  
was highest, with 3 each in accelerated phase(18%) and blast crisis(18%). One  
case of Juvenile CML, and another case of CNL, was also seen. 
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 Table 5 
Hemoglobin distribution among the cases 
 
Hb in Gram 
% 
ALL 
Nos. %
< 6 10 83%
6.1 - 9 1 9%
9.1 - 12 1 8%
12 and above 0 0%
 
 
 
Haemoglobin was seen to be less, and anemia more prevalent in acute 
leukemias than the chronic ones . ALL had as high as 83% cases with below 
6gm/dl values, followed by AML which had 71% cases . CML and CLL had 
35% and 34% respectively. 
 
AML CML 
 Nos. % Nos. % 
 17 71% 6 35% 
 6 25% 6 35% 
 1 4% 4 24% 
 0 0% 1 6% 
CLL 
Nos. % 
1 34% 
1 33% 
1 33% 
0 0% 
 
 
 
 
 Table 6 
Total leukocyte count in cases 
 
TLC 
ALL (n= 12)
Nos. %
< 4000 3 25%
4001- 11000 0 0%
11001 - 50000 4 33%
50001 - 
100000 3 25%
100001 - 
200000 2 17%
> 200000 0 0%
 
 
 
 
 
 AML (n= 24) CML (n= 17) 
 
Nos. % Nos. % 
 0 0% 0 0% 
 3 12% 0 0% 
 11 46% 3 18% 
 6 25% 4 24% 
 4 17% 5 29% 
 0 0% 5 29% 
CLL (n= 3) 
Nos. % 
1 33% 
2 67% 
0 0% 
0 0% 
0 0% 
0 0% 
 
 The total leukocyte count showed higher values of upto 50,000/µ l, in 46%  
of AML cases, and upto 100,000/µ l in 25% of them. ALL showed 33% and  
25% in the same value range. Both AML and ALL, had 33% cases with a total  
count value upto 200,000/µ l. CML, had 29% cases of total count values,  
upto and with more than 200,000/µ l. CLL, by and large had a normal range  
of total count value between 4000 to 11,000/µ l in 67% of the cases. 33% of  
CLL, and 25% of ALL, had a total count value less than 4000/µl. 
 
Table 7 
Platelet count in cases 
Platelet Count 
 / cu mm 
ALL (n= 
12) 
AML (n= 
24) 
CML (n= 
17) CLL (n= 3) 
Nos. % Nos. % Nos. % Nos. % 
< 50000 9 75% 17 71% 4 24% 0 0% 
50000 - 1 lac 1 8% 2 8% 0 0% 1 34% 
1 Lac  - 1.5 
Lacs 0 0% 1 4% 0 0% 1 33% 
> 1.5 Lacs 2 17% 4 17% 13 76% 1 33% 
 
Platelet counts were seen less than 50,000/cu.mm, in 75% of AML, and in 71%  
of ALL cases. CML, had 76% cases, with more than 100,000/cu.mm, where as  
24% had less than 50,000/cu.mm. CLL had 34% cases, upto the value of   
100.000/cu.mm, and more than 150,000/cu.mm in 33% cases. 
 
  
Table 8 
Different Hematological parameters according to the types of leukemia 
 
Parameters 
 
AML  
(n = 24) 
 
Mean SD : Hb 
(gm/dl) 
 
5.533 ± 2.77
 
Mean SD : 
TLC (per µl) 
 
56166.667    ± 
52432.25
 
Mean SD : 
Platelet Count  
( /cmm) 
 
55625.012    ±  
58268.635
 
Table 5, provides the different statistics for the haematological parameters 
according the types of leukemia. The maximum mean haemoglobin level was 
observed in CLL, followed by CML, AML and ALL, the least. The mean Total 
count, was maximum in CML, followed by ALL, AML and CLL. The mean 
platelet count ,was high in CML, followed by CLL, ALL, and least in AML. 
ALL 
 (n = 12) 
CML  
(n = 17 ) 
CLL 
(n =  3)
 4.975 ± 1.24 6.724 ± 1.68 8.601  ± 2.150
 
72343.166   
± 70265.325 
106258.824   
± 82563.265 
31900          ± 
28564.325
 
68916 .011   
± 34865.854 
226647.059   
± 123562 
162666. 66   ± 
143652.21
 
 
 
 
 
 
 
 
 
 
 
 
 Using One way Anova , by SPSS, the significance analysis of the differences in  
the group means, resulted into a  p value of  < 0.0001, and indicated , it was  
highly significant across the leukemia types. 
 
Table 9  
Comparison of clinical features with reference to haematological values  
Signs Hb  (gm/dl) 
TLC  
(/ul) 
Platelet Count                 
(Lacs /cmm) 
 
Lymphadenopathy 
 (n =  7) 
6.36 ± 
0.43 
69246.799 ± 
33672.368 
130200.565 ± 
8349.952 
Hepatomegaly 
 (n =  16) 
6.03 ± 
1.23 
63226.735 ± 
30276.269 
108775.755 ± 
51687.363 
Splenomegaly  
(n =  21) 
4.88 ± 
2.14 
47874.394 ± 
2163.351 
103181.282 ± 
32269.779 
p -Value 0.52 0.54 0.51 
 
With regards to haemoglobin, the highest mean levels were seen with cases  
having lymphadenopathy, and the lowest in cases with splenomegaly. The  
difference in mean Hb levels by one way Anova, resulted in a p value of 0.52.  
In the case of total count, the highest value was observed in patients with  
splenomegaly, and the least was seen in cases with hepatomegaly, the p value  
obtained, was 0.54. And with platelet count, the highest mean values obtained  
were in patients with lymphadenopathy, followed by hepatomegaly and the least  
in splenomegaly. The p value obtained here was 0.51.There was no statistically  
significant differences, between the group means , and the clinical features, as  
determined by one way ANOVA. 
 Immunophenotyping Results   
6 cases underwent flow cytometry,using peripheral blood samples, with 2 cases  
using regular AML panel and 3 cases with ALL panel, and with one CML case  
with its panel,  for cases suspected and doubtful. Though they showed  
cytochemical stain positive,  the results were obtained , with the plots on the  
side scatter graph. 4 cases, were concordant with the cytochemical stained  
smear diagnosis. But 2 cases of ALL, were partially concordant, and were  
requiring bone marrow aspirate samples for flow cytometry. Flow concordance  
percentage was 67%, and the remaining 33% was not in concordance, for  
peripheral blood sample. 
1) AML M2 showed CD 13, CD,33,CD,117 positivity 
2) AML M1 showed CD13, CD33 positivity 
3) ALL L1 showed CALLA positivity with CD10 gated blasts. 
4) ALL L2 showed mild blasts, but required a bone marrow aspirate analysis. 
5) CML showed CD117, CD13,CD33,CD34 positivity in the gated blasts. 
6) ALL L1 showed lymphocytosis, required a bone marrow aspirate analysis. 
 
 
 
 
 
  
 DISCUSSION 
Leukemias, as such are now common, and affects all ages and genders. It  
requires a multi parameter approach for its diagnosis, which includes  
cytomorphology study, with phenotypic and genotypic studies. In the present  
s tudy 56 cases,  were evaluated,  by studying their  morphology using  
cytochemical stains, as well as clinical features, and with 6 cases for concordant  
Immunophenotyping, using lineage specific panels with markers. Of the 56  
cases, 36 cases were acute leukemias(64%), of which 24 were AML(43%), and  
12 were ALL(22%). The rest 20 cases were chronic cases(36%), of which 17  
were CML(30%),which include one case of Chronic neutrophilic leukemia, and  
3 were CLL cases(5%). This clearly shows Acute leukemias, being more  
common than chronic ones. In the acute group, AML was more common than  
ALL, and in the chronic group CML was commoner than CLL. After subtyping  
of acute leukemias with cytochemistry, the study showed in AML, 2 cases of  
M0(8%), 6 cases of M1(25%), 13 cases of M2(55%), 1 case of M3(4%), 2 cases  
of M4(8%). No cases of M5,M6 and M7 were detected. This showed that AML  
M2 was the commonest, in the FAB classification, and was supported by studies  
too,  e .g  Kulshreshtha e t  a l .6  and a lso by other  comparat ive  s tudies .  
Comparing with other studies, population bias could be the reason, why in this  
study, AML showed higher predominance than ALL or CML. 
 
 
  
 Comparing the frequency of various leukemias in India (in percentage).7 
 
 
The above comparison , clearly shows a higher freguency of percentage in  
AML cases, in the present study, correlating with All India statistics(20 to  
Reference  
 
Region 
(PERIOD OF 
STUDY)  
No. of 
cases   
 
ALL  
 
AML  
 
CML  
 
CLL  
Chatterjee 
et al   
 
Calcutta 
(1949–
1961)  
544  
 
22.5  
 
32.5  
 
35.9  
 
5.9  
Advani et 
al   
 
Mumbai 
(1960–
1975)  
1126  
 
30  
 
13  
 
40  
 
9  
Prakash  
et al   
 
Pondicherry 
(1970–
1979)  
278  
 
35  
 
29.5  
 
30.8  
 
3.2  
Rani et al  
 
Delhi 
(1970–
1979)  
490  
 
15.5  
 
30.8  
 
45.3  
 
5.7  
            
Verghese 
et al  
 
Kerala 
(1980–
1983)  
1016  
 
39.2  
 
19.6  
 
16.4  
 
1.9  
Kushawah
a et al   
 
Lucknow 
(1971–
1984)  
970  
 
9.3  
 
38.7  
 
48  
 
2.6  
Shome  
et al   
 
Chandigarh 
(1975–
1983)  
820  
 
24  
 
29.3  
 
36.7  
 
8.8  
Dicosta 
 et al  
 
Mumbai 
(1975– 
1984)  
242  
 
36  
 
22  
 
38  
 
2  
Rathee  
et al   
 
Haryana 
(2008-2012)  
650  
 
17.2  
 
33.8  
 
39  
 
10  
Present  
study   
Thanjavur 
Tamil Nadu 
(2015-2016)  
56 
 
22 
 
43 
 
30  
 
5  
 25%).17 However, CML cases were found to be second commonest, this could  
be due to population bias, and its limitations in the study. 
Comparison of AML subtypes with previous studies in the distribution.7 
FAB 
type  
 
 
Sultanet 
al (250) 
1981  
Miguel  
et al 
(120)  
1986  
Chessells  
et al (112)  
1986  
Alvi  
et al 
(26)  
1990  
Chaudhry  
et al (54)  
1993  
Khalid 
Hassan 
(81)  
1994  
Present 
Study  
M0       8 
M1   21  13  10  15.3  13  18.5  25 
M2   32  14  26  35  44.4  23.9  54 
M3   16  14  6  15.3  11.1  11.1  5 
M4   16  22  22  19.2  24  29.6  8 
M5   12  21  24  11.5  3.7  11.1  0 
M6   3  7  9  3.7  3.7  1.2  0 
M7   0  0  0  0  0  1.2  0 
 
The subclassif ication of  AML M2 in  FAB subtypes of  AML was the  
predominant type, and was found to be correlating with the various above  
studies, except in Khalid Hassan 1994 study, where M4 was found to be higher.  
Two special stains were used in making the diagnosis, SBB and PAS, and on  
staining, myeloblasts of AML and CML showed coarse brown black granules,  
with SBB stain, with more than 3% of blasts. PAS was negative in AML. The  
lymphoblasts of ALL and CLL showed block positive with PAS stain, where as  
the myeloblasts of AML and CML were negative. 
Distribution of acute cases of leukemia as per cytochemistry. 
Out of 56 cases in total, 36 cases were acute, AML was 24,which was 67%, and  
ALL was 12, at 33%, for the cytochemical staining with both SBB, and PAS. 
cytochemistry AML ALL 
SBB+, PAS- 24 (67%) 0 
SBB - , PAS + 0 12(33%) 
TOTAL 24 12 
  
Gender distribution showed a female preponderance of leukemias as a whole in  
the study of the 56 cases. Males were of 48% and females 52%. This again  
reflects the nature of swing in the population, though generally it is commoner  
in males. AML had a higher female preponderance of 58%, against 42% in   
males, and it showed the same pattern in CML and CLL too, where as ALL had  
more males showing 67%  and females 33%. But studies show major  
differences in incidences of AML in males when compared to females,17 as seen  
here, where males are 10 and females 14 in number. 
Age distribution clearly shows ALL, predominantly in the children and early  
adolescence group, and ranges to about 92% of the cases, followed by AML  
with 42%. CML was seen more common, in the 21 to 40 age group, and CLL  
had 33% in the above 40 age group. 
Comparison with other studies.7 
Reference   Study  
Neglia, jp, and Robison.10 1988   In children, acute lymphoblastic  
leukemia (80%) is more common than acute 
myeloid leukemia  
Ribera JM, Oriol A.11 2009   Acute lymphoblastic leukemia (ALL) is the 
most frequently diagnosed malignancy in 
children,representing nearly one third of all 
pediatric cancers  
   
Present study   Acute Lymphoblastic Leukemia is more 
common  
 in age group of 0 to 20 years (92).  
 
In acute myeloid leukemia , an adult predominance was found ,and it correlated  
with previous studies too.7   
 
 Table showing the comparative study.7  
Reference  
 
Study  
Boros, L. and Bennett,  
J. M (1984)  
 
AML occurs twice as often as ALL, the vast 
majority of cases occurring in adults  
Khalid Hassan Nadeem Ikram, Sajid 
Hussain Shah13 (1994)   
 
AML was observed more commonly in 
adults (79%) as compared to children 
(21%), whereas ALL was commoner in 
children (72%) as Compared to in 28% 
amongst adults.  
   
Greer John P, Baer Maria. R, Kinney 
Marsha. C (2009)  
 
AML accounts for less than 15% of cases of 
leukemia in children below 10years, 25-
30% between 10-15 years, and in adults, it 
accounts for 80-90% of cases of acute 
leukemias.  
Present study  
 
Acute Myeloblastic Leukemias has an adult 
predominance (54%)  
 
Laboratory haematological values 
With correlation of laboratory values, Hemoglobin values, were less than 6gm%  
in 83% of ALL cases, and 71% in AML cases. 35% of CML cases, and 34% of  
CLL cases, had less than 6gm%, this clearly indicates,severe anemia as a co  
existing disorder, in cases of acute leukemia.1 ,7  The main cause being  
inadequate production of red cells and shortened life span.1 Abnormalities of  
size and shape can also occur.  
Total count values, were seen in high ranges in CML, with more than  
100,000/µ l, in 58% of cases, and as much as 29% of them had more than  
200,000/µ l, followed by AML, which had 46% of cases upto 50,000/µ l, and  
25% more than that. ALL had 33% upto 50,000/µl, and 25% in more than that.  
CLL had 67% of cases upto 11,000/µ l, and 33% less than 4000/µ l. This  
signifies that elevated counts will have less mature cells, and more of the  
 immature variety. Leucopenia is an uncommon feature.1,2   
Platelet counts in general are lower in Acute leukemias, and normal to higher or  
rarely lower in Chronic leukemias. This was interpreted in the study, and ALL  
had 75% cases with lesser values below 50,000/cu.mm, and AML had 71%  
cases, below that level. CML had normal to higher values of more than  
150,000/cu.mm in 76% of their cases.CLL had more than 66% of their cases  
with more than 100,000/cu.mm. This signifies that acute leukemias, end up with  
less production of platelets,with decreased survival, causing thrombocytopenia.1  
CML, usally has normal ranges in the chronic phase, but in the blast phase, they  
fall below the normal range just like in the acute cases. A thrombocytopenic  
picture in CML, always signals that an accelerated phase has started its process,  
leading to blast crisis.1  
Anova analysis showed the p value to be statistically significant across the  
group of means of the laboratory values, in the haematological parameters. A  
clear picture of the haematological values in assessing the Total count, platelet  
count and haemoglobin is essential in the diagnostic aid of leukemias. 
Clinical parameters  
Various  c l in ical  p resentat ions  are  seen in  leukemias ,  assessment  of  
splenomegaly, hepatomegaly and lymphadenopathy, were taken into account in  
this study. Splenomegaly was the commonest feature seen in 21 cases, followed  
by hepatomegaly in 16 cases, and 7 cases had lymphadenopathy. One particular   
feature seen here was a lesser platelet count , a lower haemoglobin value, and a  
total count less than 50.000/µl, in cases which had splenomegaly. There was no  
statistical significant differences, between the haematological value group  
 means and the clinical features, as obtained by one way Anova. The varying  
nature of the clinical features, were seen. CML invariably had splenomegaly in  
all their cases, and hepatomegaly was mixedly seen in AML , as well as CML  
and ALL. CLL cases, all had lymphadenopathy. One case of AML M3 had  
disseminated intravascular coagulopathy, and one other case of CML in chronic   
phase, had visual disturbances. 
 
Immunophenotyping 
It is important to note that, in this study, the resources were limited, and cost  
effective measures had to be undertaken for the diagnosis. In a country like  
ours, where sophisticated laboratories having flow cytometric analysis for  
immunophenotyping, are limited in number, are a costly affair.7 Hence, here  
a select few cases, were taken to undergo Flow cytometric analysis. Six cases  
were taken into account. The main purpose was to see their concordance, with  
cytochemistry. 4 cases were concordant with the flow cytometric analysis, one  
ALL, one CML, and two AML cases were found to be concordant, with  
cytochemical findings, the other two ALL cases required a bone marrow  
aspirate, and secondary markers for the lineage identity,which as per our study  
was out of our limitations.  67% were concordant, and effective in diagnosing  
the cases in our study.This correlates with the study by Belurkar S et.al 2013,  
which showed 58% concordance with flow analysis.11 Flow analysis uses a  
viable single cell suspension for the method, this consideration is important to  
note that hemodiluting effects can alter the analytical process, and can result in  
differences in results. Quality control and maintenance of equipment is highly  
 essential, which should be scrupulously followed.1  By and large, a practical  
method, in our setting would be to do a basic peripheral blood smear with  
routine stains, and with cytochemistry and morphology, a diagnosis can be  
made. In case of ambiguity or lineage specific identification, for the follow up  
of therapy and prognosis, flow cytometric analysis and cytogenetics would be of  
immense help. 
 
  
 CONCLUSION 
Leukemias are a heterogenous group of disorders, having varied clinical,  
morphological, molecular cytogenetic characteristics, and has prognostic and  
therapeutic implications on identifying them correctly. 
 
In our study, predominace of myeloid neoplasms was found more than that of  
the lymphoid ones, and AML being the commonest type noted, as per the  
statistical data, arrived at. 
 
In the age group category, ALL was seen more commonly in the childhood  
category, and AML was seen more common in the adult age group,closely  
followed by CML. 
 
The gender distribution showed a slight raise in female preponderance as a  
whole, but Male predominance was seen in ALL type, with AML and CML  
having a slight female preponderance. 
 
Anemia, as determined by Hemoglobin values, was seen more severe in Acute  
leukemias, especially in ALL and AML, where as it was mild to moderate in the  
chronic types. 
 
Leucocytosis, was seen more in CML, and AML, as well as in ALL, than in  
CLL, depicting the clonal proliferation of cells. 
 
 Thrombocytopenia was seen more in Acute leukemias, than in the chronic  
types, affirming the criteria for evaluation. 
 
Clinical features like splenomegaly were commonly present in CML, and  
hepatomegaly was evenly distributed, and lymphadenopathy in a few cases, was  
seen mostly in CLL. 
 
Cytochemical stains used were profoundly positive, in almost all cases, except  
in one case of Chronic neutrophilic leukemia. Acute leukemias were well  
studied, with the stains, SBB and PAS, and accurately classified as per FAB  
classification. 
 
With resource limitations and considering the fact, that at present, Flow  
cytometry is either not available, or beyond the capacity of poor patients in our  
country, this study was carried out, with the aim that cytochemistry would be a  
cost effective method, in diagnosing leukemias.  
 
Flow cytometry was done in a select few cases, to see the concordance with  
cytochemistry, and it did show good concordance rate as seen in our study. 
 
A leukemia diagnosis protocol, is need of the hour, considering the economics  
Involved. So a simple and effective means is to be in place for routine  
morphology, cytochemistry , so as to give a correct diagnosis, and to make it  
easily performable, in centres devoid of flow cytometric analysis. This could be  
an alternative,and an ancilliary tool, till flow cytometry and cytogenetics are  
made available. 
  
Current therapeutics and prognostic factors, rely more on flow cytometry and  
cytogenetics, and the WHO has classified leukemias on its basis. This has  
prompted a new beginning in identification of the types and morphology. Hence  
a simpler adaptive format, with cost effective means can be devised in  
countries, where there are least or no facilities, and access to them is made  
available.  
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1 16 F AML 
M2 
+VE -VE   4 5000 1 - - - - 
2 10 F AML 
M1 
+VE -VE   7 33,000 1.2 - - - - 
3 25 M AML 
M2 
+VE -VE   8.6 41,000 1.9 - - - - 
4 38 M CML 
chronic 
+VE -VE   11.7 1,20,000 2.02 + - - - 
5 2 M ALL L2 -VE +VE   3 1,12,000 2 - + + - 
6 80 M CML 
chronic 
+VE -VE   7.4 92,900 3.41 + - - - 
7 14 F ALL L1 -VE +VE   2 3,300 2.46 - + - - 
8 6 M AML 
M2 
+VE -VE   3.4 33,900 0.65 - - - - 
9 1 M ALL L2 -VE +VE   9.2 98,000 0.38 - + - - 
10 32 M AML 
M2 
+VE -VE   7.5 40,000 0.46 - - - - 
11 9 F CML 
juvenile 
+VE -VE   7 53,000 1.7 + - - - 
12 30 M AML 
M2 
+VE -VE   3 1,40,300 0.24 - + - - 
13 12 M ALL L1 -VE +VE   6 3,300 0.28 - - + - 
14 60 F AML 
M1 
+VE -VE   3.8 78,000 0.5 - + - - 
15 36 F AML 
M2 
+VE -VE CD13,CD33 
+ 
6.2 66,000 1 - - - - 
16 28 F CML 
acc 
phase 
+VE -VE   9.1 1,54,000 6.61 + - - - 
17 30 F ALL L2 -VE +VE   4.9 40,200 1 + - - - 
18 15 M ALL L2 -VE +VE   5.6 1,78,000 0.24 + + - - 
19 14 M AML 
M1 
+VE -VE   11.5 1,46,000 0.13 - - - - 
20 47 M CML 
chronic 
+VE -VE   4.8 11,300 0.26 + - - - 
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21 2 M ALL L1 -VE +VE   5.9 
1,06,000 0.46 - + - - 
22 70 F CLL -VE +VE   7.1 36,000 0.51 - +   + - 
23 18 F 
AML 
M2 
+VE -VE   2.7 
41,500 0 - - - - 
24 25 M 
CML 
acc 
phase 
+VE -VE   9.5 
2,51,700 1.53 + - - HAZY 
VISION 
25 46 F 
CML 
chronic 
+VE -VE   5 
2,08,000 2.51 + + - - 
26 14 M ALL L1 -VE +VE   3.7 56,000 0.32 - - - - 
27 4 M 
AML 
M4 
+VE -VE   4.2 
10,300 0.28 + + - - 
28 40 F 
AML 
M1 
+VE -VE   4.7 
37,000 2.01 - - - - 
29 22 F 
CML 
chronic 
+VE -VE   6.2 
1,21,500 0.1 + + - - 
30 12 M ALL L2 -VE +VE   2.8 38,000 0.4 - - - - 
31 40 F 
CML 
chronic 
+VE -VE   4 
80,000 0.46 + - - - 
32 40 F CNL -VE -VE   18.7 30,100 1.27 - - - - 
33 35 F 
AML 
M2 
+VE -VE   4.2 
21,900 0.02 - - - - 
34 93 M 
AML 
M4 
+VE -VE   6 
64,000 0.34 - - - - 
35 38 F 
CML 
chronic 
+VE -VE   5.5 
1,02,000 1.78 + - - - 
36 2 M ALL L1 -VE +VE 
CALLA 
+VE 
4.2 
37,000 0.19 - + + - 
37 17 F 
AML 
M1 
+VE -VE +VE 6.2 
14,600 0.28 - - - - 
38 10 F ALL L1 -VE +VE 
ADVICED 
BM FCM 
5.4 
3300 0.18 - + + - 
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39 75 M 
CML 
chronic 
+VE -VE 
+VE 
CD45,CD117 
7.1 
2,50,000 2.79 + - - - 
40 34 M 
CML 
blast  
+VE -VE   10.6 
2,00,000 4.22 + + - - 
41 35 M 
AML 
M1 
+VE -VE   6 
31,000 0.24 - - - - 
42 13 F 
AML 
M0 
+VE -VE   5 
52,000 0.47 - - - - 
43 18 F 
AML 
M2 
+VE -VE   6 
37,000 0.12 - - - - 
44 60 M 
AML 
M2 
+VE -VE   6.4 
68,000 0.45 - - - - 
45 1 F ALL L2 -VE 
+V
E 
MILD ↑ 
BLASTS 
ADVICED 
BM FCM 
7 
41,000 0.36 + + - - 
46 65 F CLL -VE 
+V
E 
  10.1 
29,600 2.64 + - + - 
47 46 M CLL -VE 
+V
E 
  5.4 
9800 0.97 - - + - 
48 44 F 
AML 
M0 
+VE -VE   7.4 
43,800 0.13 - - - - 
49 45 F 
AML 
M2 
+VE -VE   5.3 
1,43,900 0.42 - - - - 
50 23 F 
CML acc 
phase 
+VE -VE   5.8 
2,18,000 3.71 + - - - 
51 19 M 
AML 
M2 
+VE -VE   3.5 
53,600 0.17 - - - - 
52 35 F 
AML 
M3 
+VE -VE   4.4 
1,37,000 0.08 - - - DIC 
53 50 M 
CML 
blast 
crisis 
+VE -VE   7.8 
2,44,500 1.6 + - - - 
54 42 F 
AML 
M2 
+VE -VE   5.8 
9200 1.26 - - - - 
55 40 F 
CML 
chronic 
+VE -VE   7.8 
84,300 5.37 + - - - 
56 45 M 
CML 
BLAST 
CRISIS 
+VE -VE   5 
46,400 0.46 + + - - 
 
 ABBREVIATIONS 
FAB  - French American British Classification 
WHO – World Health Organisation 
SEER – Suveillance Epidemiology, and End Results Program 
GLOBOCAN – Global Cancer project 2012 
IARC – International Agency for Cancer Research 
AML – Acute Myeloid Leukemia 
ALL – Acute Lymphoblastic Leukemia 
CML – Chronic Myeloid Leukemia 
CLL – Chronic Lymphoid Leukemia 
MDS – Myelodysplastic Syndrome 
MPN – Myeloproliferative Neoplasms 
SBB – Sudan Black B 
PAS – Periodic acid Schiff’s reagent 
CD – Cluster of Differentiation 
FISH – Florescence insitu Hybridisation technique 
RT-PCR – Reverse Transcriptase Polymerase Chain Reaction 
BCR – Break point Cluster Region 
ABL – Abelson murine Leukemia viral oncogene homologue 1 
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APPENDIX - 1 
SUDAN BLACK B STAIN 
Preparation: 
1) Reagent stain SBB 0.3g powder is dissolved in 100ml of absolute ethanol, to  
 make a solution. 
2) Phenol buffer, is prepared by dissolving 16g og crystalline phenol in 30ml of 
 absolute ethanol. This is added with 100ml of distilled water, in which 0.3g of  
3) Disodium phosphate is dissolved. 
4) Working stain solution is made by adding 40 ml of phenol buffer with 60 ml  
 of Sudan Black prepared solution. 
Staining method: 
1) Fix the air dried blood smears with formalin vapour in a Coplin jar, after this,  
air wash the slides for 15 minutes. 
2) Immerse the smear slide in the working SBB stain solution for one hour in a   
Coplin jar, closed with a lid. 
3) After one hour, place the slide on a staining rack, and flood the slides   with70% 
alcohol, after 30 seconds, tip off the alcohol, and flood again with 70% alcohol 
for 30 seconds. Repeat the flooding three times.  
4) Rinse the smear with running tap water and air dry. 
5) Counterstain the slide with leishman stain or May-Grunwald-Giemsa stain. 
 
 
 APPENDIX – 2 
PERIODIC ACID SCHIFF’S REAGENT STAIN 
Preparation: 
1) 1% periodic acid, is made up as a solution as 10g/l in distilled water. 
2) Schiff’s reagent is made by dissolving 5gm basic fuchsin in 500ml 0f distilled  
 water. It is filtered, and the filtrate is saturated with sulphur dioxide gas by  
 bubbling for 1 to 12 hrs in a fume cup board, 2g charcoal is added for 1 minute  
 and shaken vigourously in a conical flask in the fume cupboard, and is filtered  
 immediately in a dark bottle. This reagent is stable for 6 months at room  
 temperature stored in the dark. 
Staining method: 
1) Fix the smear in methanol for 15 minutes, or in formalin vapour in a Coplin jar  
or 5 minutes, or in formal acetone for 45 seconds. 
2) Flood the slides with 1% periodic acid for 10 minutes, in a staining rack. 
3) Rinse in running tap water for 10 minutes, and air dry it. 
4) Immerse the slides in a Coplin jar containing the Schiff’s reagent, keeping it  
Covered with a lid. 
5) Rinse in running tap water for 10 minutes and air dry it. 
6) Counterstain in aqueous hematoxylin for 5 to 10 minutes, or use May-  
 Grunwald-Giemsa stain. 
 
  
 APPENDIX – 3 
Fig. 1 AML M1 SBB Positivity 
 
 
Fig. 2 AML M2 Leishman’s stain 
 
 
 Fig. 3 AML M2 SBB Positivity 
 
 
Fig. 4 CML Leishman stain 
 
 
 Fig.5 CML SBB coarse positivity 
 
 
Fig.6 ALL L1 PAS Block Positivity 
 
 
 
 Fig. 7 CLL  PAS Cytoplasmic diffuse positivity 
 
 
 
Fig. 8 AML MO Leishman stain and SBB Positivity 
            
 
 
  
 Flow cytometric analysis in a case of AML 
Flow Cytometric Analysis Rep 
Acute  Myeloid Leukemia Panel 
Sample           :   Peripheral blood   
Gating Type  :  CD 45 VS Side Scatter (Atypical Cells-33.2 %)            
 
 
  
 Blast Markers:        
      
  CD34      :  86.3%        
  HLA-DR  :  75.4%     
  
Myeloid Markers:  
                  
CD33        :  37.2% 
CD15        :  25.8% 
CD117      :  99.9% 
CD13        :  97.8%  
cMPO       :  98.4%  
 
Monocytic Markers: 
 
CD14          :  6.9% 
 
B Cell Markers: 
 
cCD79a      :  8.4 % 
 
T Cell Markers: 
 
CD7          :   9.1% 
cCD3        :   1.4% 
                                              
                                                                     
                                                                                         
 
                         
 
     
 Flow cytometric analysis in a case of ALL 
Flow Cytometric Analysis Rep 
Undifferentiated Leukemia Panel 
Sample           :   Bone marrow  
Gating Type  :  CD 45 VS Side Scatter (Atypical Cells-28 %)            
 
 
 Blast Markers:        
      
  CD34      :  18.7%        
     
  
Myeloid Markers:  
                  
CD33        :  6.8% 
CD15        :  0% 
CD117      :  0% 
CD13        :  3.6%  
cMPO       :  0.6%  
 
Monocytic Markers: 
 
CD14          :  0.2% 
 
B Cell Markers: 
 
cCD79a      : 98.4 % 
CD 10         : 54.4% 
CD 19         : 67.8% 
 
T Cell Markers: 
 
cCD3        :   3.7% 
                                              
                                                                     
                                                                                         
 
                         
 
     
